

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. email	From: Jeffrey Levi, To: Remote Addressee, Re: Greetings (1 page)	10/25/1996	Personal Misfile
002. email	From: Elizabeth Drye, To: Many Recipients, Re: Work Study/America Reads [partial] (1 page)	10/25/1996	P3/b(3)
003. email	From: www-lancet@elsevier.co.uk, To: Jeffrey Levi, Re: The Lancet User Registration [personal] [partial] (1 page)	10/25/1996	b(6)
004. email	From: Jeffrey Levi, To: Eva Margolies-Seiler, Re: STDs Among Gay Men (1 page)	10/28/1996	Personal Misfile
005. email	From: Eva Margolies-Seiler, To: Jeffrey Levi, Re: STDs Among Gay Men [personal] [partial] (2 pages)	10/28/1996	b(6)
006. email	From: 75051.3374@CompuServe.com, To: Jeffrey Levi, Re: Barby Update (2 pages)	10/28/1996	Personal Misfile
007. email	From: Jeffrey Levi, To: Carol Rasco, Re: From Your Past.... [personal] [partial] (1 page)	10/29/1996	b(6)
008. email	From: Elizabeth Drye, To: Many Recipients, Re: Education Message FYI [partial] (1 page)	10/29/1996	P3/b(3)
009. email	From: Jill Pizzuto, To: Many Recipients, Re: Kennedy Center Tickets for Nov. 6th (2 pages)	10/31/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

in437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: sym1@cpstbl.em.cdc.gov@INET@EOPMRX

CREATION DATE/TIME:25-OCT-1996 15:03:00.00

SUBJECT: Re: thank you

TO: Jeffrey Levi (LEVI_J@A1@CD) (WHO)

READ:25-OCT-1996 18:01:56.67

TEXT:

It sure can. It's a good thing people are thinking about these kinds of drug interactions; until reading the report I didn't know that protease inhibitors can retard absorption of rifamycin. I knew the rifamycin drugs could impact on the protease inhibitors, but didn't know the interaction could also lead to rifamycin toxicity. HIV-infected folks just can't catch an easy break.

>From: Jeffrey Levi
>To: sym1
>Subject: thank you
>Date: Friday, October 25, 1996 2:25PM
>
>Return-Path: <LEVI_J@a1.eop.gov>
>Received: from cdc1.cdc.gov by Smtpln.em.cdc.gov id
> <3270961E@Smtpln.em.cdc.gov>; Fri, 25 Oct 96 14:27:42 EST
>Received: from gatekeeper.eop.gov by cdc1.cdc.gov (5.0/SMI-SVR4) id
AA09889;
> Fri, 25 Oct 1996 14:26:34 -0400
>Received: from pmdf.eop.gov by gatekeeper.eop.gov;
> (5.65v3.2/1.1.8.2/17Oct95-0424PM) id AA14878; Fri, 25 Oct 1996 14:23:17
> -0400
>Received: from mr.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id
> <011B2A8JOB34002C1C@PMDF.EOP.GOV> for sym1@cpstbl.em.cdc.gov; Fri, 25
Oct
> 1996 14:26:24 -0400 (EDT)
>Received: with PMDF-MR; Fri, 25 Oct 1996 14:26:43 -0400 (EDT)
>Mr-Received: by mta DALE; Relayed; Fri, 25 Oct 1996 14:26:43 -0400
>Mr-Received: by mta EOPMRX; Relayed; Fri, 25 Oct 1996 14:26:21 -0400
>Alternate-Recipient: prohibited
>Date: Fri, 25 Oct 1996 14:25:47 -0400 (EDT)
>From: Jeffrey Levi <LEVI_J@a1.eop.gov>
>Subject: thank you
>To: sym1@cpstbl.em.cdc.gov
>Message-Id: <A2074ZWNUKMN6N*/R=CD/R=A1/U=LEVI_J/@MHS.eop.gov>
>Mime-Version: 1.0
>Content-Type: TEXT/PLAIN; CHARSET=US-ASCII
>Content-Transfer-Encoding: 7BIT
>Posting-Date: Fri, 25 Oct 1996 14:26:00 -0400 (EDT)
>Importance: normal

>Priority: normal
>Ua-Content-Id: A2074ZWNUKM6N
>X400-Mts-Identifier: [;34624152016991/3386053@CD]
>A1-Type: MAIL
>Hop-Count: 2
>content-length: 89

>-----

> thanks for sending me the mmwr....life can be complicated, can't
> it!
>
>

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:25-OCT-1996 15:03:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IB2BI35NLS002N41@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Fri, 25 Oct 1996 15:03:06 -0400 (EDT)

Received: from cdc1.cdc.gov by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01IB2BDYVDQQ000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Fri,
25 Oct 1996 14:59:49 -0700 (MST)

Received: from SmtOut.em.cdc.gov by cdc1.cdc.gov (5.0/SMI-SVR4)
id AA12705; Fri, 25 Oct 1996 15:03:03 -0400

Received: by SmtOut.em.cdc.gov with Microsoft Mail id
<32709EB1@SmtOut.em.cdc.gov>; Fri, 25 Oct 1996 15:04:17 -0500 (EST)

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Gordon P. Agress@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:25-OCT-1996 11:06:00.00

SUBJECT: Meeting with HHS on City Experiment, 10/31 11 am

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:25-OCT-1996 11:10:24.89

TO: Richard J. Turman

(Richard J. Turman@EOP@LNGTWY@EOPMRX)

READ:NOT READ

TEXT:

Message Creation Date was at 25-OCT-1996 11:00:00

I've told HHS that next Thursday, 10/31 at 11 is fine with us. They will call me back with a room number.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:25-OCT-1996 17:41:32.11

SUBJECT: ACF Meeting

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:27-OCT-1996 14:54:45.13

TEXT:

The meeting at ACF went very well. I met with the Project Officers for the ABA Resource Center and the Abandoned Infants Project. We talked about issues and possible approaches.

Bottom line was they agreed that the permanency planning issues for HIV+ parents, and all terminally ill parents, warranted special technical assistance. They feel they have the resources and will talk to the resource center and AIP and get back to me. I will follow-up to keep it moving.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 14:17:14.62

SUBJECT: fyi

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:25-OCT-1996 15:38:19.87

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-OCT-1996 14:33:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeffrey Levi

ATT SUBJECT: RE: UNSUB AIDSNEWS

ATT TO: listproc (listproc@aspensys.com@INET@EOPMRX)

TEXT:

why was I removed? i did not make this request and want to
continue to receive it!!!

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 10:50:27.08

SUBJECT: Judy F.

TO: Remote Addressee (WESTMORT@WPGATE.LAW3.GEORGETOWN.EDU@INET@EOPMRX)
READ:NOT READ

TEXT:

Should we try to get together with Judy F. before you leave...or
at least do a conference call?
thanks

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
--------------------------	---------------	------	-------------

001. email	From: Jeffrey Levi, To: Remote Addressee, Re: Greetings (1 page)	10/25/1996	Personal Misfile
------------	--	------------	------------------

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 12:00:45.06

SUBJECT: RE: Reporting System for Ryan White

TO: Virginia A. Huth (HUTH_V) (OMB)

READ:25-OCT-1996 15:28:19.64

CC: William G. White (WHITE_W) (OMB)

READ:25-OCT-1996 12:18:16.87

TEXT:

My concerns are very general:

This instrument cannot answer some very basic questions: how many people are being served? how many people are getting different kinds of services? how much money is being spent on these services? If we can't answer these questions...just what are we learning? how are the data used to make policy decisions -- either at the federal level or the grantee level (a scary thought, given how poor the data are)?

Is there a simpler, less cumbersome way to collect perhaps less, but more valuable information?

(The biggest issue here is creating a system of unique identifiers without violating confidentiality -- it is what prevented earlier efforts at reporting systems...but there should be some new thinking about this.)

Word on the street (my unscientific sample) is that most grantees don't take this seriously -- so the data they submit are not very accurate because they find it useless in their planning, evaluation, and programming.

Is an option to make HRSA sit down with OMB and grantees to find a mutually useful data collection instrument -- something that tells us what we need to know and might actually help with planning at the local level???

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 09:16:59.89

SUBJECT: STDs among gay men

TO: Remote Addressee (eam1@cpsod1.em.cdc.gov@INET@EOPMRX)
READ:NOT READ

TEXT:

There is a report in today's Washington Blade that the CDC has sent investigators to gay STD clinics to look at reports that the only population where there is a rise in gonorrhea rates is among gay men. Is this true -- that this is being looked at and this is the trend? What is being learned? If this is true -- this is obviously very alarming and has huge implications down the road. Let me know...curious....

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:25-OCT-1996 12:58:19.44

SUBJECT: FYI -- work study/america reads

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:25-OCT-1996 13:40:28.12

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:25-OCT-1996 13:08:09.03

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:25-OCT-1996 13:03:46.26

TO: Dennis Burke (BURKE_D) (OPD)
READ:25-OCT-1996 12:58:24.74

TO: Diane Regas (REGAS_D) (OPD)
READ:25-OCT-1996 14:19:46.30

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:25-OCT-1996 16:10:30.83

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:25-OCT-1996 13:00:31.80

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:27-OCT-1996 18:53:53.76

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:25-OCT-1996 16:06:48.35

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:25-OCT-1996 14:13:00.78

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:25-OCT-1996 13:00:17.71

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:25-OCT-1996 13:04:46.39

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:25-OCT-1996 13:15:38.37

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:28-OCT-1996 09:06:41.58

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:25-OCT-1996 14:25:53.62

TO: Michael Cohen (COHEN_M) (OPD)
READ:28-OCT-1996 13:00:30.96

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:25-OCT-1996 13:34:15.55

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:25-OCT-1996 13:31:48.62

TEXT:

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:25-OCT-1996 12:14:00.00

ATT CREATOR: ACCOUNT, BEAUBAIRE_D1

ATT SUBJECT: TUTOR-TP

ATT TO: Remote Addressee (SYLVIA.MATHEWS@TREAS.SPRINT.COM@INET)

ATT TO: Remote Addressee (SULLIVAN@OSDPO.SECDEF.OSD.MIL@INET)

ATT TO: Remote Addressee (HOGANJOH@JUSTICE.USDOJ.GOV@INET)

ATT TO: Remote Addressee (ANNE_SHIELDS@IOS.DOI.GOV@INET)

ATT TO: Remote Addressee (gfrazier@usda.gov@INET)

ATT TO: Remote Addressee (kthurm@os.dhhs.gov@INET)

ATT TO: Remote Addressee (ann_bormolini@postmaster2.dot.gov@INET)

ATT TO: Remote Addressee (frank_holleman@ed.gov@INET)

ATT TO: Chantale Wong (WONG_C)

ATT TO: Michelle M. Jolin (JOLIN_M)

ATT TO: Jennifer Palmieri (PALMIERI_J)

ATT TO: John C. Angell (ANGELL_J)

ATT TO: Barry J. Toiv (TOIV_B)

ATT TO: Martha Foley (FOLEY_M)

ATT TO: Janice A. Enright (ENRIGHT_J)

ATT TO: Patricia A. McHugh (MCHUGH_P)

ATT TO: Remote Addressee (jbullock@fema.gov@INET)

ATT TO: Thomas O'Donnell (ODONNELL_T)

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
002. email	From: Elizabeth Drye, To: Many Recipients, Re: Work Study/America Reads [partial] (1 page)	10/25/1996	P3/b(3)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

Freedom of Information Act - [5 U.S.C. 552(b)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

ATT TO: Elizabeth E. Drye (DRYE_E)

ATT TO: Remote Addressee (michael.cushing@opm.gov@INET)

ATT TO: Remote Addressee (b)(3)

[002]

ATT TO: Remote Addressee (brian.coyne@ssa.gov@INET)

ATT TO: Janet L. Crist (CRIST_J)

ATT TO: FAX (97364495,Thomas Donilon) (TLXA1MAIL_F:97364495\C:Thomas Donilon\\)

ATT TO: FAX (96471811,William Burns) (TLXA1MAIL_F:96471811\C:William Burns\\)

ATT TO: FAX (97367555,Elaine Shocas) (TLXA1MAIL_F:97367555\C:Elaine Shocas\\)

ATT TO: FAX (912124154029,Stuart Jones) (TLXA1MAIL_F:912124154029\C:Stuart Jones\\)

ATT TO: FAX (53390,Peter Scher) (TLXA1MAIL_F:53390\C:Peter Scher\\)

ATT TO: FAX (9260-0279,Peter Robertson) (TLXA1MAIL_F:9260-0279\C:Peter Robertson\\)

TEXT:

PRINTER FONT 13_POINT_ROMAN

PRESIDENT CLINTON PROPOSES 100,000 COLLEGE WORK STUDY
STUDENTSTO SERVE AS TUTORS TO HELP ALL CHILDREN READ WELL
BY THIRD GRADE

PRINTER FONT 11_POINT_ROMAN

October 25, 1996

PRINTER FONT 13_POINT_ROMAN

PRINTER FONT 12_POINT_ROMAN_ITALIC

As part of the President's "America Reads" Challenge to mobilize an army of tutors to ensure that every child can read well by the end of 3rd grade, President Clinton announced today a proposal to dedicate at least half of new college work study funds to community service, including 100,000 work study slots for reading tutors.

PRINTER FONT 12_POINT_ROMAN

PRESIDENT CLINTON'S "AMERICA READS" CHALLENGE: The President's America Reads Challenge, announced on August 27, 1996, is designed to address the fact that 40% of children are not reading well enough by the end of third grade. Study after study finds that sustained individualized attention and tutoring after school and over the summer can raise reading levels when combined with parental involvement and quality school instruction. To address this issue, the President's America Reads Challenge called for 30,000 reading specialists and tutor coordinators -- including 11,000 AmeriCorps members -- to help mobilize an army of reading tutors to give our children individualized attention.

NEW PROPOSAL: 100,000 WORK STUDY STUDENTS TO TUTOR CHILDREN TO READ. Today, the President takes a major step in fulfilling the America Reads Challenge and promoting his national service agenda by asking that a significant portion of the new increases in

college work study funding be dedicated to tutoring children to read independently by the end of the third grade.

* Reach 1 Million College Work Study Participants: In FY1996, college work study received \$617 million and went to 713,000 students. In FY1997, college work study received a 35% increase to over 900,000 students -- a major step toward the President's State of the Union promise to reach 1 million work study participants by FY2000. Steady yearly increases will allow the nation to easily reach and surpass the President's goal of 1 million work study students.

* At Least Half of College Work Study Increase Dedicated to Community Service: Currently, schools are required to dedicate only 5% of their work study slots to community service. The President called on colleges and universities to dedicate the new money to community service and will propose legislation to require that at least half of all increases beyond the FY1996 level be committed to community service -- particularly to tutoring children to read. By committing at least half of the increase above the funding level that had been flat in nominal terms for several years, schools will be able to use these funds for community service for children and tutoring without disrupting any existing arrangements.

* Work Study Dedicated to Creating 100,000 Tutors: The President's initiative asks that the public service work study slots be used to mobilize 100,000 work study students to tutor children in reading by FY1999.

* Waive Match for Work Study Funds Spent on Tutoring: In current work study programs, schools receive 75% of the wages for a work study student, but must match the remaining 25%. The President's proposal would waive the school match where work study students are placed as tutors for children.

* Further Expansion of National Service: This proposed dedication of new work study funds to community service and tutoring positions represents a major expansion of the President's national service agenda. The America Reads Challenge already called for 11,000 AmeriCorps members to build on the success of National Service programs like AmeriCorps and RSVP seniors volunteers in building and coordinating effective tutoring programs. This initiative adds 100,000 more young people each year to the President's national service strategy -- in the cause of helping all children learn to read independently.

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
003. email	From: www-lancet@elsevier.co.uk, To: Jeffrey Levi, Re: The Lancet User Registration [personal] [partial] (1 page)	10/25/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: www-lancet@elsevier.co.uk@INET@EOPMRX

CREATION DATE/TIME:25-OCT-1996 10:33:00.00

SUBJECT: The Lancet User Registration

TO: levi_j (levi_j@a1@CD) (WHO)
READ:25-OCT-1996 10:36:38.32

TEXT:

Thank you for registering to use The Lancet's web site.

Please visit the site regularly to keep up-to-date with developments
in medical science and practice

Here is confirmation of your user name and password:

(b)(6)

[003]

Please take note of these details as you will need them to access The Lancet site at <http://www.thelancet.com>.

Should you forget your password or experience any difficulty
connecting to the site, please contact us by e-mail on
www-lancet@elsevier.co.uk

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:25-OCT-1996 10:33:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IB2236JYW0002CN5@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 25 Oct 1996 10:33:00 -0400 (EDT)

Received: from skiddaw.elsevier.co.uk (skiddaw.elsevier.co.uk)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01IB21XCP9GI00007K@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 25 Oct 1996 10:29:07 -0700 (MST)

Received: (from htbin@localhost) by skiddaw.elsevier.co.uk (8.8.2/8.8.0)
id PAA13719; Fri, 25 Oct 1996 15:31:49 +0100 (BST)

Errors-to: www-lancet@elsevier.co.uk

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Virginia A. Huth (HUTH_V) (OMB)

CREATION DATE/TIME:25-OCT-1996 11:39:34.69

SUBJECT: Reporting System for Ryan White

TO: William G. White (WHITE_W) (OMB)

READ:25-OCT-1996 12:17:54.22

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:25-OCT-1996 11:42:06.75

TEXT:

I have scheduled a meeting with HRSA on the Ryan White package for Wednesday, October 30 from 10 -12. I will find a conference room and let you know where.

We need to send them some questions or an outline by middle of next week. How would you care to proceed? Shall we meet next Monday or Tuesday? Perhaps Tuesday afternoon after the BBB?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 14:28:48.51

SUBJECT: life is complicated

TO: Remote Addressee (WESTMORT@WPGATE.LAW3.GEORGETOWN.EDU@INET@EOPMRX)
READ:NOT READ

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:25-OCT-1996 14:19:00.00

ATT BODYPART TYPE:E

ATT CREATOR: Wm G. White

ATT SUBJECT: MMWR 10/25/96: Impact of HIV Protease Inhibitors on TB

ATT TO: LEVI_J (LEVI_J@A1@CD)

TEXT:
Message Creation Date was at 25-OCT-1996 14:19:00

----- Forwarded by Wm G. White/OMB/EOP on 10/25/96 02:20 PM

Gordon P. Agress

10/25/96 02:00:01 PM

Record Type: Record

To: Richard J. Turman/OMB/EOP, Wm G. White/OMB/EOP, Victoria A.
Wachino/OMB/EOP, Marc Garufi/OMB/EOP

cc:

Subject: MMWR 10/25/96: Impact of HIV Protease Inhibitors on TB

Here is a CDC item on the interaction of a TB drug and protease inhibitors.
----- Forwarded by Gordon P. Agress/OMB/EOP on 10/25/96 02:00
PM -----

server @ aspensys.com
10/25/96 12:58:00 PM

Record Type: Record

To: Gordon P. Agress

cc:

Subject: MMWR 10/25/96: Impact of HIV Protease Inhibitors on TB

MORBIDITY AND MORTALITY WEEKLY REPORT

Centers for Disease Control and Prevention

October 25, 1996

Vol. 45/No. 42

Notice to Readers

Clinical Update: Impact of HIV Protease Inhibitors on the
Treatment of HIV-Infected Tuberculosis Patients with Rifampin

In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs: saquinavir (Invirase TM), zidovudine (Norvir TM), and didanosine (Crixivan TM). Another drug in this class of agents, zalcitabine (Viracept TM) (Agouron Pharmaceuticals), is expected to be available soon from the manufacturer through an expanded-access program. All four drugs, which inhibit HIV protease and thus interfere with viral maturation and replication, are the most potent antiretroviral agents available to treat patients with HIV disease (1). However, these protease inhibitors interact with rifamycin derivatives, such as rifampin and rifabutin, which are used to treat and prevent the mycobacterial infections commonly observed in HIV-infected patients. Rifamycins accelerate the metabolism of protease inhibitors (through induction of hepatic P450 cytochrome oxidases), resulting in subtherapeutic levels of the protease inhibitors. In addition, protease inhibitors retard the metabolism of rifamycins, resulting in increased serum levels of rifamycins and the likelihood of increased drug toxicity (2). This report describes approaches for managing patients who are candidates for or who are undergoing protease inhibitor therapy when tuberculosis (TB) is diagnosed and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued.

BACKGROUND

Rifampin is an essential component of the currently recommended regimen for treating TB (3). This regimen is efficacious in treating HIV-infected patients with TB and consists of isoniazid and rifampin for a minimum of 6 months, plus pyrazinamide and either ethambutol or streptomycin for the first 2 months (4,5). Therefore, the pharmacokinetic interactions between protease inhibitors and rifampin are important for health-care workers involved in TB control and the care of patients co-infected with TB and HIV because clinicians may decrease or restrict the use of rifampin in the treatment of patients who are candidates for therapy with both protease inhibitors and rifampin. Prompt initiation of appropriate drug therapy for patients with HIV infection who acquire TB is critical because TB may be rapidly fatal (6). Drug therapy is a critical personal health measure for

curing TB and minimizes the impact of this disease on the progression of HIV infection; in addition, drug therapy is a major public health measure for interrupting the transmission of *Mycobacterium tuberculosis* to persons in the community.

Currently, the manufacturers' product labeling for protease inhibitors contraindicates, does not recommend, or discourages the concurrent administration of rifampin and protease inhibitors. Because of the common association of TB and HIV infection, an increasing number of patients probably will be considered candidates for rifampin and protease inhibitors. The management of these patients is complex, requires an individualized approach, and should be undertaken only by or in consultation with an expert. In addition, all HIV-infected patients at risk for TB infection should be carefully evaluated and administered isoniazid for preventive treatment if indicated, regardless of their status for being prescribed protease inhibitor therapy.

MANAGEMENT OPTIONS

TB Management for Patients for Whom Protease Inhibitor Therapy Is Being Considered but Has Not Yet Been Initiated

For HIV-infected patients diagnosed with drug-susceptible TB and for whom protease inhibitor therapy is being considered but has not been initiated, the suggested management strategy is to complete TB treatment with a regimen containing rifampin before starting therapy with a protease inhibitor. The duration of this anti-TB regimen is at least 6 months, and therapy should be administered following current guidelines published by the American Thoracic Society and CDC (3), including the recommendation to carefully assess clinical and bacteriologic response in patients co-infected with HIV and to prolong treatment if response is slow or suboptimal. Antiretroviral agents other than protease inhibitors may be used concurrently with this regimen. Directly observed therapy (DOT) is routinely recommended for the treatment of TB to ensure adherence with the recommended regimen and is available through local health department TB-control programs. Among patients who adhere to therapy, four-drug regimens are expected to be effective even in those infected with strains of *M. tuberculosis* resistant to isoniazid or streptomycin alone. However, the management of patients with drug-resistant TB should be evaluated on a case-by-case basis and individualized based on the results of drug-susceptibility studies.

TB Management Options for Patients Undergoing Protease Inhibitor Therapy

There are three options for managing HIV-infected patients with TB who are undergoing protease inhibitor therapy when TB is diagnosed. One option is to discontinue therapy with the protease inhibitor while undergoing a TB treatment regimen that includes rifampin. However, because of the potential that interruptions in the administration of the prescribed protease inhibitor can

induce HIV resistance to the protease inhibitor and possibly to other drugs within the protease inhibitor class (1) and because discontinuation of protease inhibitor therapy may be associated with a detrimental effect on the patient's clinical status, some clinicians may be reluctant to discontinue protease inhibitor therapy for the duration of TB treatment. In such cases, two additional options may be considered. Because the risks and benefits of all these options are unknown, clinicians should individualize management decisions on a case-by-case basis to provide optimal patient care.

Option I. This option involves discontinuing therapy with the protease inhibitor and completing a short (minimum 6 months) course of TB treatment with a regimen containing rifampin. This anti-TB regimen should be administered following current guidelines published by the American Thoracic Society and CDC (3), and the duration of therapy should be prolonged in patients with slow or suboptimal responses. Protease inhibitor therapy may be resumed when treatment with rifampin is discontinued. Antiretroviral agents other than protease inhibitors may be used concurrently with rifampin. Although the risks associated with a complete discontinuation of protease inhibitor therapy while undergoing TB treatment are unclear, they may be serious; however, the risks and complications associated with TB treatment regimens that do not include rifampin are known. Potential consequences include prolonged duration of therapy to at least 18–24 months, increased likelihood of treatment failure and mortality (7, 8), slower conversion of sputum culture to negative with patients remaining infectious for longer periods of time, and the adverse effect of TB disease on the progression of HIV infection (9,10). Therefore, nonrifampin-containing regimens are not recommended for the treatment of rifampin-susceptible TB.

Option II. To minimize the interruption of protease inhibitor therapy, one option is to use a four-drug TB treatment regimen that includes rifampin (i.e., daily isoniazid, pyrazinamide, rifampin, and ethambutol or streptomycin) for a minimum of 2 months and until bacteriologic response is achieved (i.e., sputum conversion to culture-negative status), and the results from susceptibility testing are available. After bacteriologic response and drug susceptibility have been documented (usually 3 months), treatment may be modified to a 16-month continuation-phase regimen consisting of isoniazid (15 mg/kg) and ethambutol (50 mg/kg) two times per week. This regimen allows the reintroduction of protease inhibitor therapy. Some experts consulted for this report recommended adding a third drug, such as streptomycin, during this continuation phase if the infecting organism is not resistant to the drug. Option II cannot be recommended for patients with proven isoniazid-resistant TB.

Option III. The other management option is to continue protease inhibitor therapy with indinavir (800 mg every 8 hours) and administer a four-drug, 9-month TB-treatment regimen containing daily rifabutin (150 mg/day) instead of rifampin. When this

option is used for TB management, clinicians should conduct careful monitoring, possibly including measuring serum concentrations of rifabutin, a service available only in specialized centers in the United States. This alternative TB therapy is recommended based on the pharmacokinetic characteristics of rifabutin and limited data from clinical trials. Rifabutin is a rifamycin derivative with comparable anti-TB activity in vitro but with less hepatic P450 cytochromic enzyme-inducing effect than rifampin (11, 12). An international multicenter study indicated that a 6-month regimen containing rifabutin, at the daily dose of either 150 mg or 300 mg, was as effective for treating TB as a similar regimen containing rifampin (13). In a small clinical trial, a rifabutin-containing regimen was effective in treating TB in patients co-infected with HIV (14). In addition, limited data from pharmacokinetic studies suggest that the combination of rifabutin at 150 mg/day and indinavir resulted in acceptable levels of both drugs (15). Option III cannot be recommended for patients undergoing therapy with ritonavir or saquinavir. For these patients, the decision to change the prescribed protease inhibitor to indinavir and to prescribe rifabutin for TB therapy should be made in consultation with an expert in the use of protease inhibitors to manage HIV infection. In the United States, rifabutin is approved by FDA for the prevention of disease caused by *M. avium* complex (MAC) but not for the treatment or prevention of TB.

ADDITIONAL RECOMMENDATIONS

Neither option II nor option III have been studied in large clinical trials of HIV-infected patients or patients undergoing protease inhibitor therapy during TB treatment. For these reasons, if either of these options are selected for managing patients with TB, CDC recommends the following interim guidelines until additional data are available and formal guidelines are issued: 1) on initiation of therapy, perform frequent bacteriologic evaluations to document sputum conversion to culture-negative status, and after culture conversion, to detect any possible treatment failures, 2) extend the duration of therapy to at least 18 months for option II or 9 months for option III, 3) use only indinavir with option III, 4) carefully monitor for drug toxicity, 5) use DOT throughout, and 6) reevaluate periodically during the first 2 years after completion of therapy (including an assessment of bacteriologic status at six months) and instruct patients to promptly report symptoms compatible with relapse of TB disease. The management of HIV-infected patients diagnosed with drug-resistant TB or diagnosed clinically with TB but without culture and susceptibility-testing results should be evaluated on a case-by-case basis and performed in consultation with a TB expert.

CONCLUSIONS

In the future, concurrent use of protease inhibitors with rifampin might be possible by modifying the doses of both to compensate for the drug interaction. For example, based on limited data submitted to FDA during the new drug application

review for ritonavir, a slight increase in the dosage of ritonavir and a reduction by half in the dosage of rifampin may have resulted in satisfactory levels of both drugs. However, this option cannot be recommended until data from larger, more detailed studies are available and will require careful monitoring of the serum levels of rifampin.

Interactions between protease inhibitors and the rifamycins also have complicated prophylaxis and treatment for disseminated MAC disease. Rifabutin is one of the drugs recommended for MAC prophylaxis (16). According to the manufacturer of indinavir, rifabutin at half the dose (150 mg) can be used for MAC prophylaxis simultaneously with indinavir. Other options for MAC prophylaxis are clarithromycin and azithromycin (17,18), two macrolide antibiotics approved by FDA for this purpose and for which interactions with protease inhibitors are expected to be less of an issue. In November 1996, a joint working group of the Public Health Service and Infectious Disease Society of America will update recommendations for MAC prophylaxis.

To reduce the likelihood of drug interactions while providing optimal anti-TB care for HIV-infected persons, health-care workers involved in the care of patients with TB and health-care workers involved in HIV clinical care are encouraged to coordinate efforts and thus ensure the best possible outcome for these patients. CDC's Research and Evaluation Branch, Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, (telephone [404] 639-8123)) requests the inclusion of clinical information in the comments section of TB surveillance reports from private practitioners or health department staff who manage HIV-infected patients undergoing protease inhibitor therapy when TB is diagnosed.

Reported by: Center for Drug Evaluation and Research, Food and Drug Administration. Div of Tuberculosis Elimination, and Div of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, CDC.

References

1. Bartlett JG. Protease inhibitors for HIV infection. *Ann Int Med* 1996;124:1086_8.
2. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increase risk of rifabutin-associated adverse event [Abstract no. B.171]. Presented at XI International Conference on AIDS. Vancouver, July 8, 1996.
3. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. *Am J Respir Crit Care Med* 1994;149:1359_74.
4. Small PM, Schechter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1991;324:289_94.
5. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled

- trial of treatment for either 6 or 12 months. *N Engl J Med* 1995;332:779_84.
6. Iseman MD. Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 1993;329:784_91.
7. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with standard chemotherapy in Kinshasa, Zaire. *Am Rev Respir Dis* 1991;144:750_5.
8. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. *Lancet* 1994;344:1323_8.
9. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. *Am J Respir Crit Care Med* 1995;151:129_35.
10. Wallis RS, Helfand MS, Whalen C, et al. Immune activation, allergic drug toxicity, and mortality in HIV-positive tuberculosis. *Tubercle Lung Dis* (in press).
11. Kunin CM. Antimicrobial activity of rifabutin. *Clin Infect Dis* 1996;22(suppl 1):S3_S14.
12. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. *Clin Infect Dis* 1996;22(suppl 1):S15_S22.
13. McGregor M, Olhano P, Wolmarans L, et al. Efficacy and safety of rifabutin in patients with newly-diagnosed pulmonary tuberculosis. *Am J Respir Crit Care Med* (in press).
14. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. *Tubercle Lung Dis* 1995;76:210_8.
15. The Indinavir (MK 639) Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies. Presented at the XI International Conference on AIDS. Vancouver, July 8, 1996.
16. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. *MMWR* 1995;44(no. RR-8):1_34.
17. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated *Mycobacterium avium* complex (MAC) infection in patients with advanced acquired immunodeficiency syndrome. *N Engl J Med* 1996;335:384_91.
18. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated *Mycobacterium avium* complex with weekly azithromycin, daily rifabutin, or both. *N Engl J Med* 1996;335:392_8. HIV Protease Inhibitors _ Continued

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:25-OCT-1996 14:27:00.00

ATT BODYPART TYPE:D

TEXT:

The following attachments were included with this message:

TYPE : FILE

NAME : 102513A3.TXT

===== END ATTACHMENT 2 =====

===== ATTACHMENT 3 =====

ATT CREATION TIME/DATE:25-OCT-1996 14:27:00.00

ATT BODYPART TYPE:D

ATT SUBJECT: 102513A3

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011B275MBPC0003J3V@PMDf.EOP.GOV> for
agress_g@al.eop.gov; Fri, 25 Oct 1996 12:58:32 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <011B271C4PAS000080@STORM.EOP.GOV> for
agress_g@al.eop.gov; Fri, 25 Oct 1996 12:55:05 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA27661; Fri,
25 Oct 1996 12:58:19 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 3 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:25-OCT-1996 15:40:25.24

SUBJECT: RE: daily news

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:27-OCT-1996 14:54:30.60

TEXT:

I will follow-up with Aspen. I think we talked about getting individual mailings awhile ago.

Hope you have a good weekend.

Jane

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:25-OCT-1996 09:52:19.78

SUBJECT: tickler update - attached

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:25-OCT-1996 09:56:20.35

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:25-OCT-1996 10:27:53.91

TO: Dennis Burke (BURKE_D) (OPD)
READ:25-OCT-1996 10:44:34.78

TO: Pamela Cicetti (CICETTI_P) (WHO)
READ:25-OCT-1996 09:55:37.54

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:25-OCT-1996 09:58:58.87

TO: Deborah L. Fine (FINE_D) (OPD)
READ:25-OCT-1996 10:18:49.85

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:25-OCT-1996 10:28:07.07

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:27-OCT-1996 22:12:50.70

TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ:25-OCT-1996 10:54:23.15

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:25-OCT-1996 10:25:10.07

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:25-OCT-1996 10:25:19.28

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:25-OCT-1996 09:58:51.48

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:25-OCT-1996 10:00:05.04

TO: Bruce N. Reed (REED_B) (WHO)
READ:25-OCT-1996 14:50:03.33

TO: Diane Regas (REGAS_D) (OPD)
READ:25-OCT-1996 11:09:36.96

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:25-OCT-1996 10:08:46.82

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:25-OCT-1996 11:24:53.31

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:28-OCT-1996 09:06:26.80

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:25-OCT-1996 14:39:48.53

TO: Michael Cohen (COHEN_M) (OPD)
READ:25-OCT-1996 09:55:19.52

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:25-OCT-1996 09:52:54.03

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:25-OCT-1996 10:53:48.80

TO: Claudia M. Rayford-Williams (RAYFORDWIL_C) (OPD)
READ:28-OCT-1996 11:40:45.14

TO: FAX (9720-5166,Larry Elworth / Fran (TLXA1MAIL_\\F:9720-5166\\C:Larry Elworth / Fran\\)
READ:NOT READ

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:25-OCT-1996 10:38:09.76

TO: Mia Masten (MASTEN_M) (OPD)
READ:25-OCT-1996 10:53:41.46

TEXT:

Please remember to get back to me if some of these things have been worked on -- some of the dates are outdated.

EED: regarding "other WH staff" who were asked to do a few things, my guess is that these things have already been handled given the dates - can I delete them off the list?

PRINTER FONT 12_POINT_COURIER
TICKLER FILE (as October 15, 1996)
BEN - AMI, JEREMY

*10/17 - action with Treasury on White House event on Low-Vision feature on Currency (*under DF name too)

BROSTROM, MOLLY
BURKE, DENNIS

*10/7 - response to Bersin letter (in process)

*9/11 - status of POTUS response to Califano letter
(currently read by POTUS; POTUS to discuss w/Califano)

*7/15 - response on the support of upcoming legislation on
Character Research and Therapy

COHEN, MIKE

*9/13 - status of grant for Edcouch - Elsa School District
(Delta Area Empowerment Sub

-Zone)

*8/6 - follow

-up to Jamie Frakes' fax / Higher Education Act

*7/17 - response regarding memo to POTUS regarding Fred

Taylor

CRAFT, DOROTHY K.

*9/17 - response to sixth grade class'project on world

hunger

DRYE, ELIZABETH

*10/17 - action with Tresury on White House Event on New Low
Visi

on Feature on Currency

*10/2 - continuing response to Donald McGee - VT health

care/ concerned citizen

*10/2 - handling of Partnership Express request to be

considered as a Federal Project

*9/13 - discussion on fax/ issues from Nat'l Assoc. of State

Alco

hol and Drug Abuse Directors

*7/30 - reply to request for POTUS to support Oregon's plan
for universal health care

FINE, DEBBIE

FLEMING, PATSY

*10/17 - response to Navajo AIDS Network on Ryan White Care
Act and funding concerns

*10/17 - comments on recommendations from Dr. Satcher and

AIDS Action Council

FORTUNA, DIANA

*10/18 - UCP Humanitarian Award Invitation for POTUS -

follow

-up with scheduling and Mack McLarty

*10/17 - action with Treasury on White House Event on Low-
Vision Feature on Currency (*under JBA too)

*10/17 - "substantive" response for Nat'l Coalition for

Family Leadership, NOTE REPLY DATE

*10/17 - response for Georgia Hospital Association on SSI

concerns, NOTE REPLY DATE

*10/2 - response to Nat'l Easter Seal Society about SSI

HOGAN, LYN

*10/17 - discussion on letter from Center for Reproductive
Law and Policy concerning Little Rock Family Planning

Services vs. Dalton

*10/17 - response to Paul Mones' letter; thank you following
visi

t already sent

JENNINGS, CHRIS

*10/18 - provisions/process of implementation for new mental
heal
th insurance guidelines in reference to Cheryl Verlander
request

*9/24 - follow up note to Mack McLarty, re: Jack Krol, DE
health care legislation

KLEIN, JENNIFER
LEVI, JEFF
PIZZUTO, JILL

RAYFORD

-WILLIAMS, CLAUDIA
REGAS, DIANE

*10/17 - briefing from NEC, etc.,
concerning letter from the Int'l Union of
Operating Engineers (after Nov.5)
SMARTT, JEANINE

*10/17 - draft response to Governor's Cabinet on Children
and Families, NOTE REPLY DATE
WARNATH, STEVE

*9/10 - answer to POTUS on Golden Venture Detainees Issue
*5/28 - discussion on DPC draft concerning benefits for
illegal and legal immigrants
*3/11 - reply to People of the Golden Vision concerning the
stat
us of the immigrants of the Golden Venture detained by INS

WEINSTEIN, PAUL
*5/10 - continued follow

-up on the RGV Empowerment Zone
*3/11 - follow

-up on letter from Sen. Lockyer's office
concerning the proposed reform legislation and ensuring the
protection of child welfare

OTHER WHITE HOUSE STAFF
BROMBERG, EMILY

*9/11 - handling Chiles letter as per Jeremy's request
O'CONNOR, JENNIFER
*8/21 - formulate response (if needed) to Nat'l Assoc. of
Evangelicals concerning tobacco legislation.

SHEA, TOM
*9/23 - response to Iowa tribe of Oklahoma concernig the
University of Missouri's possession of Native American
remains

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Wm G. White@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:25-OCT-1996 14:26:00.00

SUBJECT: MMWR 10/25/96: Impact of HIV Protease Inhibitors on TB

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:25-OCT-1996 14:34:25.47

TEXT:

Message Creation Date was at 25-OCT-1996 14:19:00

----- Forwarded by Wm G. White/OMB/EOP on 10/25/96 02:20 PM

Gordon P. Agress

10/25/96 02:00:01 PM

Record Type: Record

To: Richard J. Turman/OMB/EOP, Wm G. White/OMB/EOP, Victoria A.
Wachino/OMB/EOP, Marc Garufi/OMB/EOP

cc:

Subject: MMWR 10/25/96: Impact of HIV Protease Inhibitors on TB

Here is a CDC item on the interaction of a TB drug and protease inhibitors.

----- Forwarded by Gordon P. Agress/OMB/EOP on 10/25/96 02:00
PM -----

server @ aspensys.com

10/25/96 12:58:00 PM

Record Type: Record

To: Gordon P. Agress

cc:

Subject: MMWR 10/25/96: Impact of HIV Protease Inhibitors on TB

MORBIDITY AND MORTALITY WEEKLY REPORT

Centers for Disease Control and Prevention

October 25, 1996

Vol. 45/No. 42

Notice to Readers

Clinical Update: Impact of HIV Protease Inhibitors on the
Treatment of HIV-Infected Tuberculosis Patients with Rifampin

In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs: saquinavir (Invirase TM), zidovudine (Norvir TM), and didanosine (Crixivan TM). Another drug in this class of agents, zalcitabine (Viracept TM) (Agouron Pharmaceuticals), is expected to be available soon from the manufacturer through an expanded-access program. All four drugs, which inhibit HIV protease and thus interfere with viral maturation and replication, are the most potent antiretroviral agents available to treat patients with HIV disease (1). However, these protease inhibitors interact with rifamycin derivatives, such as rifampin and rifabutin, which are used to treat and prevent the mycobacterial infections commonly observed in HIV-infected patients. Rifamycins accelerate the metabolism of protease inhibitors (through induction of hepatic P450 cytochrome oxidases), resulting in subtherapeutic levels of the protease inhibitors. In addition, protease inhibitors retard the metabolism of rifamycins, resulting in increased serum levels of rifamycins and the likelihood of increased drug toxicity (2). This report describes approaches for managing patients who are candidates for or who are undergoing protease inhibitor therapy when tuberculosis (TB) is diagnosed and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued.

BACKGROUND

Rifampin is an essential component of the currently recommended regimen for treating TB (3). This regimen is efficacious in treating HIV-infected patients with TB and consists of isoniazid and rifampin for a minimum of 6 months, plus pyrazinamide and either ethambutol or streptomycin for the first 2 months (4,5). Therefore, the pharmacokinetic interactions between protease inhibitors and rifampin are important for health-care workers involved in TB control and the care of patients co-infected with TB and HIV because clinicians may decrease or restrict the use of rifampin in the treatment of patients who are candidates for therapy with both protease inhibitors and rifampin. Prompt initiation of appropriate drug therapy for patients with HIV infection who acquire TB is critical because TB may be rapidly fatal (6). Drug therapy is a critical personal health measure for curing TB and minimizes the impact of this disease on the progression of HIV infection; in addition, drug therapy is a major public health measure for interrupting the transmission of *Mycobacterium tuberculosis* to persons in the community.

Currently, the manufacturers' product labeling for protease inhibitors contraindicates, does not recommend, or discourages the concurrent administration of rifampin and protease inhibitors. Because of the common association of TB and HIV infection, an increasing number of patients probably will be considered candidates for rifampin and protease inhibitors. The management of these patients is complex, requires an individualized approach, and should be undertaken only by or in

consultation with an expert. In addition, all HIV-infected patients at risk for TB infection should be carefully evaluated and administered isoniazid for preventive treatment if indicated, regardless of their status for being prescribed protease inhibitor therapy.

MANAGEMENT OPTIONS

TB Management for Patients for Whom Protease Inhibitor Therapy Is Being Considered but Has Not Yet Been Initiated

For HIV-infected patients diagnosed with drug-susceptible TB and for whom protease inhibitor therapy is being considered but has not been initiated, the suggested management strategy is to complete TB treatment with a regimen containing rifampin before starting therapy with a protease inhibitor. The duration of this anti-TB regimen is at least 6 months, and therapy should be administered following current guidelines published by the American Thoracic Society and CDC (3), including the recommendation to carefully assess clinical and bacteriologic response in patients co-infected with HIV and to prolong treatment if response is slow or suboptimal. Antiretroviral agents other than protease inhibitors may be used concurrently with this regimen. Directly observed therapy (DOT) is routinely recommended for the treatment of TB to ensure adherence with the recommended regimen and is available through local health department TB-control programs. Among patients who adhere to therapy, four-drug regimens are expected to be effective even in those infected with strains of *M. tuberculosis* resistant to isoniazid or streptomycin alone. However, the management of patients with drug-resistant TB should be evaluated on a case-by-case basis and individualized based on the results of drug-susceptibility studies.

TB Management Options for Patients Undergoing Protease Inhibitor Therapy

There are three options for managing HIV-infected patients with TB who are undergoing protease inhibitor therapy when TB is diagnosed. One option is to discontinue therapy with the protease inhibitor while undergoing a TB treatment regimen that includes rifampin. However, because of the potential that interruptions in the administration of the prescribed protease inhibitor can induce HIV resistance to the protease inhibitor and possibly to other drugs within the protease inhibitor class (1) and because discontinuation of protease inhibitor therapy may be associated with a detrimental effect on the patient's clinical status, some clinicians may be reluctant to discontinue protease inhibitor therapy for the duration of TB treatment. In such cases, two additional options may be considered. Because the risks and benefits of all these options are unknown, clinicians should individualize management decisions on a case-by-case basis to provide optimal patient care.

Option I. This option involves discontinuing therapy with the protease inhibitor and completing a short (minimum 6 months)

course of TB treatment with a regimen containing rifampin. This anti-TB regimen should be administered following current guidelines published by the American Thoracic Society and CDC (3), and the duration of therapy should be prolonged in patients with slow or suboptimal responses. Protease inhibitor therapy may be resumed when treatment with rifampin is discontinued. Antiretroviral agents other than protease inhibitors may be used concurrently with rifampin. Although the risks associated with a complete discontinuation of protease inhibitor therapy while undergoing TB treatment are unclear, they may be serious; however, the risks and complications associated with TB treatment regimens that do not include rifampin are known. Potential consequences include prolonged duration of therapy to at least 18-24 months, increased likelihood of treatment failure and mortality (7, 8), slower conversion of sputum culture to negative with patients remaining infectious for longer periods of time, and the adverse effect of TB disease on the progression of HIV infection (9,10). Therefore, nonrifampin-containing regimens are not recommended for the treatment of rifampin-susceptible TB.

Option II. To minimize the interruption of protease inhibitor therapy, one option is to use a four-drug TB treatment regimen that includes rifampin (i.e., daily isoniazid, pyrazinamide, rifampin, and ethambutol or streptomycin) for a minimum of 2 months and until bacteriologic response is achieved (i.e., sputum conversion to culture-negative status), and the results from susceptibility testing are available. After bacteriologic response and drug susceptibility have been documented (usually 3 months), treatment may be modified to a 16-month continuation-phase regimen consisting of isoniazid (15 mg/kg) and ethambutol (50 mg/kg) two times per week. This regimen allows the reintroduction of protease inhibitor therapy. Some experts consulted for this report recommended adding a third drug, such as streptomycin, during this continuation phase if the infecting organism is not resistant to the drug. Option II cannot be recommended for patients with proven isoniazid-resistant TB.

Option III. The other management option is to continue protease inhibitor therapy with indinavir (800 mg every 8 hours) and administer a four-drug, 9-month TB-treatment regimen containing daily rifabutin (150 mg/day) instead of rifampin. When this option is used for TB management, clinicians should conduct careful monitoring, possibly including measuring serum concentrations of rifabutin—a service available only in specialized centers in the United States. This alternative TB therapy is recommended based on the pharmacokinetic characteristics of rifabutin and limited data from clinical trials. Rifabutin is a rifamycin derivative with comparable anti-TB activity in vitro but with less hepatic P450 cytochromic enzyme-inducing effect than rifampin (11, 12). An international multicenter study indicated that a 6-month regimen containing rifabutin, at the daily dose of either 150 mg or 300 mg, was as effective for treating TB as a similar regimen containing rifampin (13). In a small clinical trial, a rifabutin-containing

regimen was effective in treating TB in patients co-infected with HIV (14). In addition, limited data from pharmacokinetic studies suggest that the combination of rifabutin at 150 mg/day and indinavir resulted in acceptable levels of both drugs (15). Option III cannot be recommended for patients undergoing therapy with ritonavir or saquinavir. For these patients, the decision to change the prescribed protease inhibitor to indinavir and to prescribe rifabutin for TB therapy should be made in consultation with an expert in the use of protease inhibitors to manage HIV infection. In the United States, rifabutin is approved by FDA for the prevention of disease caused by *M. avium* complex (MAC) but not for the treatment or prevention of TB.

ADDITIONAL RECOMMENDATIONS

Neither option II nor option III have been studied in large clinical trials of HIV-infected patients or patients undergoing protease inhibitor therapy during TB treatment. For these reasons, if either of these options are selected for managing patients with TB, CDC recommends the following interim guidelines until additional data are available and formal guidelines are issued: 1) on initiation of therapy, perform frequent bacteriologic evaluations to document sputum conversion to culture-negative status, and after culture conversion, to detect any possible treatment failures, 2) extend the duration of therapy to at least 18 months for option II or 9 months for option III, 3) use only indinavir with option III, 4) carefully monitor for drug toxicity, 5) use DOT throughout, and 6) reevaluate periodically during the first 2 years after completion of therapy (including an assessment of bacteriologic status at six months) and instruct patients to promptly report symptoms compatible with relapse of TB disease. The management of HIV-infected patients diagnosed with drug-resistant TB or diagnosed clinically with TB but without culture and susceptibility-testing results should be evaluated on a case-by-case basis and performed in consultation with a TB expert.

CONCLUSIONS

In the future, concurrent use of protease inhibitors with rifampin might be possible by modifying the doses of both to compensate for the drug interaction. For example, based on limited data submitted to FDA during the new drug application review for ritonavir, a slight increase in the dosage of ritonavir and a reduction by half in the dosage of rifampin may have resulted in satisfactory levels of both drugs. However, this option cannot be recommended until data from larger, more detailed studies are available and will require careful monitoring of the serum levels of rifampin.

Interactions between protease inhibitors and the rifamycins also have complicated prophylaxis and treatment for disseminated MAC disease. Rifabutin is one of the drugs recommended for MAC prophylaxis (16). According to the manufacturer of indinavir, rifabutin at half the dose (150 mg) can be used for MAC prophylaxis simultaneously with indinavir. Other options for MAC

prophylaxis are clarithromycin and azithromycin (17,18), two macrolide antibiotics approved by FDA for this purpose and for which interactions with protease inhibitors are expected to be less of an issue. In November 1996, a joint working group of the Public Health Service and Infectious Disease Society of America will update recommendations for MAC prophylaxis.

To reduce the likelihood of drug interactions while providing optimal anti-TB care for HIV-infected persons, health-care workers involved in the care of patients with TB and health-care workers involved in HIV clinical care are encouraged to coordinate efforts and thus ensure the best possible outcome for these patients. CDC's Research and Evaluation Branch, Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, (telephone [404] 639-8123)) requests the inclusion of clinical information in the comments section of TB surveillance reports from private practitioners or health department staff who manage HIV-infected patients undergoing protease inhibitor therapy when TB is diagnosed.

Reported by: Center for Drug Evaluation and Research, Food and Drug Administration. Div of Tuberculosis Elimination, and Div of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, CDC.

References

1. Bartlett JG. Protease inhibitors for HIV infection. *Ann Int Med* 1996;124:1086_8.
2. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increase risk of rifabutin-associated adverse event [Abstract no. B.171]. Presented at XI International Conference on AIDS. Vancouver, July 8, 1996.
3. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. *Am J Respir Crit Care Med* 1994;149:1359_74.
4. Small PM, Schechter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1991;324:289_94.
5. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. *N Engl J Med* 1995;332:779_84.
6. Iseman MD. Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 1993;329:784_91.
7. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with standard chemotherapy in Kinshasa, Zaire. *Am Rev Respir Dis* 1991;144:750_5.
8. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. *Lancet* 1994;344:1323_8.

9. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. *Am J Respir Crit Care Med* 1995;151:129_35.
10. Wallis RS, Helfand MS, Whalen C, et al. Immune activation, allergic drug toxicity, and mortality in HIV-positive tuberculosis. *Tubercle Lung Dis* (in press).
11. Kunin CM. Antimicrobial activity of rifabutin. *Clin Infect Dis* 1996;22(suppl 1):S3_S14.
12. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. *Clin Infect Dis* 1996;22(suppl 1):S15_S22.
13. McGregor M, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in patients with newly-diagnosed pulmonary tuberculosis. *Am J Respir Crit Care Med* (in press).
14. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. *Tubercle Lung Dis* 1995;76:210_8.
15. The Indinavir (MK 639) Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies. Presented at the XI International Conference on AIDS. Vancouver, July 8, 1996.
16. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. *MMWR* 1995;44(no. RR-8):1_34.
17. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated *Mycobacterium avium* complex (MAC) infection in patients with advanced acquired immunodeficiency syndrome. *N Engl J Med* 1996;335:384_91.
18. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated *Mycobacterium avium* complex with weekly azithromycin, daily rifabutin, or both. *N Engl J Med* 1996;335:392_8.

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:25-OCT-1996 14:27:00.00

ATT BODYPART TYPE:D

TEXT:
The following attachments were included with this message:

TYPE : FILE
NAME : 102513A3.TXT

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:25-OCT-1996 14:27:00.00

ATT BODYPART TYPE:D

ATT SUBJECT: 102513A3

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01IB275MBPC0003J3V@PMDf.EOP.GOV> for
agress_g@a1.eop.gov; Fri, 25 Oct 1996 12:58:32 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <01IB271C4PAS000080@STORM.EOP.GOV> for
agress_g@a1.eop.gov; Fri, 25 Oct 1996 12:55:05 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA27661; Fri,
25 Oct 1996 12:58:19 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 14:15:26.80

SUBJECT: RE: daily news

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:25-OCT-1996 15:37:36.38

TEXT:

they sent me an e-mail announcing they were taking me off -- but with no reason -- I replied saying I wanted on -- but nothing happened -- maybe you could call them and see what it takes for all of us to get it directly.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 14:16:38.33

SUBJECT: as mentioned

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:25-OCT-1996 15:38:02.67

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-OCT-1996 09:13:00.00

ATT BODYPART TYPE:E

ATT CREATOR: listproc

ATT SUBJECT: UNSUB AIDSNEWS

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

You have been removed from list aidsnews@cdcnac.aspensys.com.

Thanks for being with us.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:21-OCT-1996 09:15:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)

id <01IAWE6B659S0038YM@PMDF.EOP.GOV> for levi_j@a1.eop.gov; Mon,
21 Oct 1996 09:14:23 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IAWE649SAO006Q47@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Mon, 21 Oct 1996 09:14:13 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01IAWE1TXFDA00007K@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Mon, 21 Oct 1996 09:10:47 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id JAA10256; Mon,
21 Oct 1996 09:13:49 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

X-Comment: Aspen Systems List Server

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:25-OCT-1996 13:04:09.55

SUBJECT: daily news

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:25-OCT-1996 14:14:40.46

TEXT:

Have the daily news stopped coming? If it would be easier I'd be happy to put myself on the mailing list....

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:25-OCT-1996 09:07:32.36

SUBJECT: Counseling and testing project

TO: Remote Addressee (dcade@hcfa.gov@INET)

READ:NOT READ

TEXT:

Any word on someone from Medicaid who can participate in the CDC, HRSA, et al. effort to look at how counseling and testing for HIV have changed in light of new technologies and new treatments? The date for the meeting is now set for December 19 and 20 in San Francisco -- it would be great if someone from HCFA could be part of the planning. Please let me know ASAP. Thanks.

Jeff Levi

202-632-1090

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Christopher C. Jennings (JENNINGS_C) (WHO)

CREATION DATE/TIME:27-OCT-1996 21:31:42.80

SUBJECT: RE: tomorrow at 2

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:28-OCT-1996 08:41:40.25

TEXT:

Sorry I got back so late to you on this. I have been traveling and overwhelmed with paperwork.

Nothing like fishing for compliments, sorry. Glad to be of help.

Re the DPC idea, I think it has real potential. If you pursue it seriously, talk with Nancy Ann Min about it to lay some groundwork and to see if she would be happy about it. Since she has the resources and much of the jurisdiction, she has the power to make it sink or swim.

Also, I would suggest pushing a little bit on the disability angle. Although Diana Fortuna is doing this, Carol wants this to be such a high priority for the next Administration that she may need help. (Although there is still the question as to whether Carol will be sticking around.) There may be an angle for you to get involved -- perhaps from the special populations/PHS angle?? Let's talk sometime about it, ok?

cj

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:27-OCT-1996 14:55:24.98

SUBJECT: RE: ACF Meeting

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:28-OCT-1996 10:53:09.87

TEXT:

you should also report on this to Lynn, et al. Sounds good.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:27-OCT-1996 14:58:19.70

SUBJECT: draft option

TO: Remote Addressee (aimeec@gwis2.circ.gwu.edu@INET)
READ:NOT READ

TEXT:
PRINTER FONT 12_POINT_COURIER
Aimee--

I am sending this to you by fax and electronically. It's my crack at the bill of rights option -- it needs editing (it's too long) and we need a better selection of potential rights. Go at it -- no pride of authorship.
Jeff

Bill of Rights Option:

One option that has been proposed by consumer advocates is to legislate a consumer bill of rights for managed care [note: I have gone headlong into legislation...I think it just is setting up a straw man to talk about doing this administratively] -- designed to level the playing field between the consumer and the managed care health plan. The range of so

-called rights that could be considered is broad -- but the underlying goal is to establish structural assurances that the individual has a greater say in determining how his/her care is delivered; that the health plan does not have total control.

Among the standard "rights" that are often proposed are:

- * Timely access to appropriate care.
- * Affordable choice of providers.
- * Comprehensive benefits package.
- * Access to affordable health care free of financial barriers.
- * Quality health care (i.e., quality assurance programs).
- * Ability to challenge or appeal decisions made by a plan.
- * Accurate, current and understandable information about a plan.
- * Confidentiality of records and non

-discrimination in delivery of care.

- * Representation in decision making and in the organization and regulation of managed care.
- * Vigorous enforcement of the bill of rights.

[Note: some of these should be deleted; some are part of other options; which of these need to be defined for the purpose of this presentation?]

A basic policy question is whether this approach should be done at the state level or the federal level. States have long

been considered the "laboratory" for experimentation with new approaches to public policy problems. In fact, states have begun to address this issue, with 33 states taking up legislation of some kind regulating HMOs. But this has been piecemeal at best -- with only New York adopting a comprehensive approach to this problem. Of greatest concern, however, is the limit on the reach of state legislatures. States can only regulate Medicaid plans and some private HMOs -- usually those serving smaller employers. This leaves out the xx million Americans cared for under Medicare, and under the terms of ERISA, the states do not have legislative authority over many private plans -- which leaves 114 million Americans outside state purview. Only federal legislation would have the scope necessary to cover all who are in managed care and thus have the same floor of rights established across the nation. Nothing in the federal legislation, however, should preclude the states from passing

stronger legislation for those within their jurisdiction. (One could imagine providers, if they fail to block federal legislation, to argue that the federal law be the ceiling, not the floor, to allow for consistency of approach everywhere.)

At this juncture, we are proposing consideration of the bill of rights option in a general sense. Should you decide to move forward with this option, we propose a series of discussions with consumer and provider groups to determine which elements should be included in our legislative package -- based on what is most important and most likely to generate broad (or at least sufficient) political support.

Our equity criterion requires a federal approach. If protection is needed, then its availability should not be dependent on geography or whether one is in a plan subject to state regulation.

Would this approach be effective? The answer to that is theoretical. We have no direct experience with these provisions; the New York law was just enacted. However, it is based on the plausible notion that the right for patients to have more say in health care decisions will improve health outcomes -- if one accepts the view that this element of control is the difference between fee

-for

-service plans and managed care plans that resulted in the disparity of quality care (health outcomes) in several studies discussed earlier.

Is this politically feasible? Some kind of consumer protection is popular. The breadth of the bill of rights -- who is covered and its scope -- will determine the level of opposition. While likely to be equally effective (or ineffective) regardless of whether it covers Medicaid, Medicare, or private plans -- the larger the scope of the regulation, the more potential opposition may develop. Limiting to the public sector (Medicare and Medicaid), would eliminate potential opposition from large employers, who have significant clout.

(There might also be opposition from some large unions, who see the scope of health benefits as one of the things they can bargain over with employers, and do not want government intrusion.) An argument could be made that the maximum political benefit would accrue from addressing the Medicare concerns (though this is volatile -- as we saw from previous attempts), since the Medicaid population is less vocal politically (though also least able to advocate for themselves). In the end, however, the success of such an effort would depend on building broad

-based popular support. This would argue for an approach that covers all payors of health care -- public and private -- but the selection of "rights" that will minimize opposition from those invested in the status quo. (Clearly, the providers of managed care will resist a bill of rights -- unless

they can be convinced that this is a battle worth resolving at the federal level, so as to avoid a state

-by

-state fight.)

This is a relatively broad

-based approach. By establishing "rights" and processes rather than defining very specific standards of care, this should be an approach that is adaptable to the changing health care delivery environment.

Finally, cost is a significant unknown. In New York State, no estimates were made for the potential cost of the bill of rights -- in terms of lower profits for HMOs and/or increased premiums for the consumer. Clearly, some would have cost implications (e.g., the choice of providers), while others would have small or negligible cost (e.g., confidentiality). As specific elements of potential legislation are considered, this should be part of the decision making regarding which rights to include.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:28-OCT-1996 09:11:20.22

SUBJECT: query

TO: Ashley L. Raines (RAINES_A) (OA)

READ:28-OCT-1996 10:05:05.47

TEXT:

Can we give Daniel Montoya an all-in-one account? He's doing a lot of work with the Advisory Council, and we do a lot of communicating with them via e-mail. Thanks...

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Patsy Fleming (FLEMING_P) (WHO)

CREATION DATE/TIME:28-OCT-1996 16:15:54.95

SUBJECT: SSA/HCFA mtg

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:28-OCT-1996 18:11:19.42

TEXT:

Would you please send me a copy of the e-mail.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:28-OCT-1996 12:43:30.58

SUBJECT: REMINDERS FOR CHR SCHEDULE / THIS WEEK

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:28-OCT-1996 14:29:11.68

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:28-OCT-1996 13:53:46.55

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:28-OCT-1996 12:56:57.75

TO: Dennis Burke (BURKE_D) (OPD)
READ:28-OCT-1996 13:09:07.49

TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ:28-OCT-1996 13:09:40.51

TO: Michael Cohen (COHEN_M) (OPD)
READ:28-OCT-1996 14:58:40.79

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:28-OCT-1996 13:45:09.44

TO: Deborah L. Fine (FINE_D) (OPD)
READ:11-NOV-1996 16:49:15.78

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:28-OCT-1996 12:44:38.43

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:28-OCT-1996 12:54:42.58

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:29-OCT-1996 07:46:29.82

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:28-OCT-1996 13:36:21.77

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:28-OCT-1996 12:44:38.06

TO: Mia Masten (MASTEN_M) (OPD)
READ:28-OCT-1996 13:17:57.52

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:28-OCT-1996 12:46:54.63

TO: Claudia M. Rayford-Williams (RAYFORDWIL_C) (OPD)
READ:28-OCT-1996 12:52:24.60

TO: Diane Regas (REGAS_D) (OPD)
READ:28-OCT-1996 14:07:51.73

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:28-OCT-1996 14:15:44.54

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:28-OCT-1996 13:13:23.65

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:28-OCT-1996 15:46:11.74

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:28-OCT-1996 13:43:51.33

TEXT:

Tuesday, 10/29:

Jennings / Klein: staffing the 2:30 meeting. NO paper needed

Drye: staffer needed for 3:30p

Wednesday, 10/30:

JBA / DF: paper needed for 10:00a meeting

JBA / DF: Update needed for NGA weekly @ 1:00p

Lyn: paper needed for Child welfare chat

Thursday, 10/31:

EED: staffer for the 10:00a Joan Lombardi (Jeanine & Lyn?); NO paper needed

Paul Weinstein: staffing Rural Devel. meeting; paper due Wed. by 4:30p

JBA/DF: ?update needed for 1:00p bi-weekly?

Lyn: child welfare paper

Friday, 11/01:

Cohen: staffing 11:00a w/ JD Hoyer; NO paper needed

DF: paper needed for the 1:15

please let me know if there are any questions. DEADLINE FOR RECEIVING BRIEFING

PAPERS IS 4:30P - ALWAYS, unless notified that I need it earlier.

Thanks.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
004. email	From: Jeffrey Levi, To: Eva Margolies-Seiler, Re: STDs Among Gay Men (1 page)	10/28/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: RBlock@hcfa.gov@INET@EOPMRX

CREATION DATE/TIME:28-OCT-1996 12:27:00.00

SUBJECT: The brain does not always work.... -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:28-OCT-1996 12:43:46.54

TEXT:

Fine with me - I think we're scheduled for 2-4 at the Law Project offices.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:28-OCT-1996 12:27:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01IB6CY0VWMO006D1C@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Mon, 28 Oct 1996 12:27:22 -0400 (EDT)

Received: from hcfa.gov (158.73.85.22) by STORM.EOP.GOV (PMDf V5.0-7 #6879)
id <01IB6EX6K1B4000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Mon,
28 Oct 1996 13:23:57 -0700 (MST)

Received: from HCFA-Message_Server by hcfa.gov with Novell_GroupWise; Mon,
28 Oct 1996 12:25:02 -0500

X-Mailer: Novell GroupWise 4.1

Content-disposition: inline

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:28-OCT-1996 18:19:57.98

SUBJECT: RE: AIDS form letter

TO: Sarah S. Freeman (FREEMAN_S) (WHO)

READ:29-OCT-1996 11:30:21.45

TEXT:
the letter looks good!

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:28-OCT-1996 08:51:55.05

SUBJECT: The brain does not always work....

TO: Remote Addressee (rblock@hcfa.gov@INET)
READ:NOT READ

TEXT:

I have put on my calendar going to Philadelphia on November 15th...is this when you are meeting with the folks re the PA waiver? If so -- is there a specific time -- since I might want to combine this with some other things? (I assume you have no problem with my tagging along -- if this IS a problem, I am happy to withdraw.)

Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:28-OCT-1996 18:21:38.81

SUBJECT: I'll be late in the morning

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:28-OCT-1996 19:01:59.13

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:29-OCT-1996 12:17:09.96

TO: Carmena Parris (PARRIS_C) (OPD)

READ:29-OCT-1996 07:16:50.11

TO: Lahoma Romocki (ROMOCKI_L) (OPD)

READ:30-OCT-1996 08:57:41.56

TEXT:

I am having breakfast with Kerry Lobel, the new ED of NGLTF, so I will be a little late on Tuesday morning.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:28-OCT-1996 10:15:28.08

SUBJECT: Re: RE(wr): STDs among gay men

TO: Margolies-Seiler, Eva Z. (eam1@cpsod1.em.cdc.gov@INET@EOPMRX)
READ:NOT READ

TEXT:
yes i do still need the info...thanks...glad you had a good time.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: eam1@cpsod1.em.cdc.gov@INET@EOPMRX

CREATION DATE/TIME:28-OCT-1996 07:53:00.00

SUBJECT: RE(wr): STDs among gay men

TO: 'Jeffrey Levi' (LEVI_J@A1@CD) (WHO)

READ:28-OCT-1996 08:42:11.94

TEXT:

I will be out of the office October 21 - 25th. If you need immediate assistance please call Gary Conrad or Carol McCurley at 639-8008.

From: Jeffrey Levi
To: eam1
Subject: STDs among gay men
Date: Friday, October 25, 1996 9:21 AM

Return-Path: <LEVI_J@a1.eop.gov>
Received: from cdc1.cdc.gov by Smtpln.em.cdc.gov id
<32704D93@Smtpln.em.cdc.gov>; Fri, 25 Oct 96 09:18:11 EST
Received: from gatekeeper.eop.gov by cdc1.cdc.gov (5.0/SMI-SVR4) id AA15693;
Fri, 25 Oct 1996 09:17:00 -0400
Received: from pmdf.eop.gov by gatekeeper.eop.gov;
(5.65v3.2/1.1.8.2/17Oct95-0424PM) id AA22178; Fri, 25 Oct 1996 09:13:42
-0400
Received: from mr.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id
<011B1ZERQPUO003A07@PMDF.EOP.GOV> for eam1@cpsod1.em.cdc.gov; Fri, 25
Oct
1996 09:16:50 -0400 (EDT)
Received: with PMDF-MR; Fri, 25 Oct 1996 09:17:09 -0400 (EDT)
Mr-Received: by mta DALE; Relayed; Fri, 25 Oct 1996 09:17:09 -0400
Mr-Received: by mta EOPMRX; Relayed; Fri, 25 Oct 1996 09:16:47 -0400
Alternate-Recipient: prohibited
Date: Fri, 25 Oct 1996 09:15:28 -0400 (EDT)
From: Jeffrey Levi <LEVI_J@a1.eop.gov>
Subject: STDs among gay men
To: eam1@cpsod1.em.cdc.gov
Message-Id: <A1829ZWNUD9FYV*/R=CD/R=A1/U=LEVI_J/@MHS.eop.gov>
Mime-Version: 1.0
Content-Type: TEXT/PLAIN; CHARSET=US-ASCII
Content-Transfer-Encoding: 7BIT
Posting-Date: Fri, 25 Oct 1996 09:16:00 -0400 (EDT)
Importance: normal
Priority: normal
Ua-Content-Id: A1829ZWNUD9FYV
X400-Mts-Identifier: [;90719052016991/3383563@CD]
A1-Type: MAIL

Hop-Count: 2
content-length: 487

--

There is a report in today's Washington Blade that the CDC has sent investigators to gay STD clinics to look at reports that the only population where there is a rise in gonorrhea rates is among gay men. Is this true -- that this is being looked at and this is the trend? What is being learned? If this is true -- this is obviously very alarming and has huge implications down the road. Let me know...curious....

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:28-OCT-1996 07:53:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011B63DSQBPC000MDD@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Mon, 28 Oct 1996 07:53:45 -0400 (EDT)

Received: from cdc1.cdc.gov by STORM.EOP.GOV (PMDf V5.0-7 #6879)
id <011B65CYPZ4A000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Mon,
28 Oct 1996 08:50:21 -0700 (MST)

Received: from SmtOut.em.cdc.gov by cdc1.cdc.gov (5.0/SMI-SVR4)
id AA03898; Mon, 28 Oct 1996 07:52:49 -0500

Received: by SmtOut.em.cdc.gov with Microsoft Mail id
<32742E74@SmtOut.em.cdc.gov>; Mon, 28 Oct 1996 07:54:28 -0500 (EST)

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: WESTMORT@WPGATE.LAW3.GEORGETOWN.EDU@INET@EOPMRX

CREATION DATE/TIME:28-OCT-1996 14:59:00.00

SUBJECT: life is complicated -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:28-OCT-1996 15:01:43.39

TEXT:

Auggghh. Life is extremely complicated. Maybe this
is a good issue for the Forum to study.

TMW

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:28-OCT-1996 14:59:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011B6I92L1N40083G4@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Mon, 28 Oct 1996 14:59:03 -0400 (EDT)

Received: from WPGATE.LAW3.GEORGETOWN.EDU by STORM.EOP.GOV (PMDf V5.0-7 #6879)
id <011B6K88JW4O000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Mon,
28 Oct 1996 15:55:39 -0700 (MST)

Received: from LAWCAMPUS-Message_Server by WPGATE.LAW3.GEORGETOWN.EDU with
Novell_GroupWise; Mon, 28 Oct 1996 16:01:40 -0500

X-Mailer: Novell GroupWise 4.1

Content-disposition: inline

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
005. email	From: Eva Margolies-Seiler, To: Jeffrey Levi, Re: STDs Among Gay Men [personal] [partial] (2 pages)	10/28/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: eam1@cpsod1.em.cdc.gov@INET@EOPMRX

CREATION DATE/TIME:28-OCT-1996 09:31:00.00

SUBJECT: Re: RE(wr): STDs among gay men

TO: Jeffrey Levi (LEVI_J@A1@CD) (WHO)

READ:28-OCT-1996 10:18:07.21

TEXT:

[005]

(b)(6)

....do

you still want the info. on STDs among gay men.

Eva

From: Jeffrey Levi
To: Margolies-Seiler, Eva Z.
Subject: RE: RE(wr): STDs among gay men
Date: Monday, October 28, 1996 8:42AM

Return-Path: <LEVI_J@a1.eop.gov>
Received: from cdc1.cdc.gov by Smtpln.em.cdc.gov id
<32743A2A@Smtpln.em.cdc.gov>; Mon, 28 Oct 96 08:44:26 EST
Received: from gatekeeper.eop.gov by cdc1.cdc.gov (5.0/SMI-SVR4) id AA06161;
Mon, 28 Oct 1996 08:42:43 -0500
Received: from pmdf.eop.gov by gatekeeper.eop.gov;
(5.65v3.2/1.1.8.2/17Oct95-0424PM) id AA20180; Mon, 28 Oct 1996 09:39:19
-0500
Received: from mr.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id
<01IB653EIHWCW007HON@PMDf.EOP.GOV> for eam1@cpsod1.em.cdc.gov; Mon, 28
Oct
1996 08:42:39 -0400 (EDT)
Received: with PMDF-MR; Mon, 28 Oct 1996 08:42:36 -0400 (EDT)
Mr-Received: by mta DALE; Relayed; Mon, 28 Oct 1996 08:42:36 -0400
Mr-Received: by mta EOPMRX; Relayed; Mon, 28 Oct 1996 08:42:35 -0400
Alternate-Recipient: prohibited
Date: Mon, 28 Oct 1996 08:42:18 -0400 (EDT)
From: Jeffrey Levi <LEVI_J@a1.eop.gov>
Subject: RE: RE(wr): STDs among gay men
In-Reply-To: <32742E74@Smtpln.em.cdc.gov>
To: "Margolies-Seiler, Eva Z." <eam1@cpsod1.em.cdc.gov>
Message-Id: <A1623ZWNXCFV31*/R=CD/R=A1/U=LEVI_J/@MHS.eop.gov>
Mime-Version: 1.0
Content-Type: TEXT/PLAIN; CHARSET=US-ASCII
Content-Transfer-Encoding: 7BIT
Posting-Date: Mon, 28 Oct 1996 08:42:00 -0400 (EDT)
Importance: normal
Priority: normal
Ua-Content-Id: A1623ZWNXCFV31
X400-Mts-Identifier: [;63248082016991/3396316@CD]

AI-Type: MAIL
Hop-Count: 2
content-length: 106

--
(b)(6)

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:28-OCT-1996 09:31:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IB66SLQUXC00643C@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Mon, 28 Oct 1996 09:31:12 -0400 (EDT)

Received: from cdc1.cdc.gov by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01IB68RRNK8M000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Mon,
28 Oct 1996 10:27:47 -0700 (MST)

Received: from SmtOut.em.cdc.gov by cdc1.cdc.gov (5.0/SMI-SVR4)
id AA09029; Mon, 28 Oct 1996 09:31:02 -0500

Received: by SmtOut.em.cdc.gov with Microsoft Mail id
<3274457A@SmtOut.em.cdc.gov>; Mon, 28 Oct 1996 09:32:42 -0500 (EST)

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Sarah S. Freeman (FREEMAN_S) (WHO)

CREATION DATE/TIME:28-OCT-1996 16:31:48.73

SUBJECT: AIDS form letter

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:28-OCT-1996 18:11:20.85

TEXT:

would you take a look at the AIDS form letter in its final version? OMB slightly changed a couple of numbers and Maureen Hudson checked the name of the law and found out it should be the "Omnibus Consolidated Appropriations Act, 1996" (this name change has not been made yet in the following copy.)

I need to know the letter is now correct. Please let me know today if possible because Maureen needs to send out two messages immediately that use this language. Thanks, as always, for your great help.

p-302 AIDS

Thank you for your message about the AIDS epidemic. I'm glad you took the time to let me know your views.

This past year has brought new reason for hope and optimism. New drugs are showing very promising results in halting the progress of HIV disease. But, as my recent visit to the NAMES Quilt on the Mall, here in Washington, made clear, too many of our friends and loved ones are dying of this terrible disease and there is still a great deal of work to do. I am committed to building on our work and strengthening our national leadership in the war against AIDS.

That is why I am so pleased by the recent enactment of the Omnibus Appropriations and Immigration Act of 1996. That new law includes substantial, across-the-board increases in funding for AIDS research, prevention, treatment, and housing. It increases funds for the Ryan White CARE Act by 31.5 percent and triples funding specifically set aside for the AIDS Drug Assistance Program, which helps thousands of people living with HIV gain access to life-extending treatments.

I was also pleased that Congress agreed to delete provisions in the immigration reform act that would have unfairly penalized legal immigrants living with HIV/AIDS. Discrimination against people living with this disease goes against all that we believe in as Americans.

Finally, I am gratified that we were successful in preserving the Medicaid safety net. More than 50 percent of Americans living with AIDS -- including more than 90 percent of children with AIDS -- rely on Medicaid as a lifeline of support. I have vetoed one bill that would have taken away that guarantee of coverage, and I will do so again if Congress ever passes such a bill again.

I remain committed to fighting HIV and AIDS. Working together, we can defeat AIDS and create a more secure future for all of us.

I appreciate your interest in this most important issue.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
006. email	From: 75051.3374@CompuServe.com, To: Jeffrey Levi, Re: Barby Update (2 pages)	10/28/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Richard J. Turman@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:29-OCT-1996 22:44:00.00

SUBJECT: Re: HRSA strikes again...

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:30-OCT-1996 08:36:54.40

TEXT:

Message Creation Date was at 29-OCT-1996 22:40:00

Thanks for keeping us in the loop.

Sorry for not getting back to you today. Right now is actually the first time I've had to read e-mail, much less return phone calls, all day. We were in meetings with NEM for 7 hours during the past 24 hours, so it has been a bit chaotic.

We'll chat tomorrow for the Thursday session.

Thanks!

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: WESTMORT@WPGATE.LAW3.GEORGETOWN.EDU@INET@EOPMRX

CREATION DATE/TIME:29-OCT-1996 09:55:00.00

SUBJECT: Since I don't trust new voice mail

TO: Levi_J (Levi_J@A1@CD) (WHO)

READ:29-OCT-1996 10:04:42.66

TEXT:

Since I don't trust new voice mail (from personal experience with my own), I'm sending the other modern technology message to ask you to call me when you have a chance. I want to talk about (1) possible dinner with Chai and Anne before I leave and (2) Judy Feder.

Thanks.

TMW

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:29-OCT-1996 09:56:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IB7LWRCRVK009S3F@PMDF.EOP.GOV> for
Levi_J@a1.eop.gov; Tue, 29 Oct 1996 09:55:14 -0400 (EDT)

Received: from WPGATE.LAW3.GEORGETOWN.EDU by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01IB7NVVFKIM000080@STORM.EOP.GOV> for Levi_J@a1.eop.gov; Tue,
29 Oct 1996 10:51:47 -0700 (MST)

Received: from LAWCAMPUS-Message_Server by WPGATE.LAW3.GEORGETOWN.EDU with
Novell_GroupWise; Tue, 29 Oct 1996 10:57:45 -0500

X-Mailer: Novell GroupWise 4.1

Content-disposition: inline

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:29-OCT-1996 13:27:36.63

SUBJECT: Hot Issues

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:29-OCT-1996 14:31:21.19

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:29-OCT-1996 14:30:05.12

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:29-OCT-1996 13:29:29.65

TO: Dennis Burke (BURKE_D) (OPD)
READ:29-OCT-1996 18:30:51.04

TO: Diane Regas (REGAS_D) (OPD)
READ:29-OCT-1996 14:04:41.06

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:29-OCT-1996 14:24:28.27

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:29-OCT-1996 13:28:59.64

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:29-OCT-1996 15:03:20.29

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:29-OCT-1996 14:17:56.14

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:29-OCT-1996 17:28:26.71

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:29-OCT-1996 13:30:23.34

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:29-OCT-1996 13:33:45.11

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:29-OCT-1996 14:55:02.93

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:29-OCT-1996 13:35:18.68

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:29-OCT-1996 17:49:01.92

TO: Michael Cohen (COHEN_M) (OPD)
READ:29-OCT-1996 13:27:45.58

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:29-OCT-1996 13:27:53.72

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:29-OCT-1996 13:56:58.86

TEXT:

Staff Secretary is collecting paragraphs on hot issues by Wednesday COB for Las Cruces, San Antonio, Los Angeles, New Orleans, Little Rock, Tampa, and NJ. Let me know if you have anything.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: CRitter@hcfa.gov@INET@EOPMRX

CREATION DATE/TIME:29-OCT-1996 09:44:00.00

SUBJECT: Evaluating Criteria -Reply -Forwarded

TO: levi_j (levi_j@A1@CD) (WHO)
READ:29-OCT-1996 10:02:33.90

TEXT:

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:29-OCT-1996 09:40:00.00

ATT BODYPART TYPE:E

ATT CREATOR: Christina Ritter

ATT SUBJECT: Evaluating Criteria -Reply

ATT TO: levi_j (levi_j@a1.cop.gov@INET@EOPMRX)

ATT TO: jmintz (jmintz@aol.com@INET@EOPMRX)

ATT TO: aimeec (aimeec@gwis2.circ.gwu.edu@INET@EOPMRX)

ATT TO: culoj (culoj@gwis2.circ.gwu.edu@INET@EOPMRX)

TEXT:

To Aimee et al.

Now everyone knew that I couldn't resist an opportunity to comment - right?

I was thinking about this myself, mostly with regard to threshold criteria. I had focused my attention on threshold criteria because we have to justify why we have included some options and not others. I really think that this could be our weakest point. Last Thursday we discussed that perhaps one threshold criteria for inclusion would be : alternatives that do not interfere with the market structure of managed care. To me, this threshold makes the assumption that we in some way or another approve of managed care's structure/cost containment focus - but are trying to insert quality into the equation. Using this threshold, we dropped two alternatives: requiring choice among health plans, and requiring patient participation on health plan's board of trustees. I have to admit that I am not yet convinced that this is the threshold we should choose to drop these options, mostly because I do not know a lot about the whole market structure and because I am not sure that other options we consider do not interfere with the market structure. For example, doesn't direct access to specialists under the consumer bill of rights also interfere with the market structure? As always, I am open to a good argument in support of this threshold. However, we may have to find

another way to weed. We could always have a political feasibility threshold that uses previous state legislation as a criterion...although I doubt that Catron would find that convincing.

As for ranking among other criteria, We had briefly discussed color ranges, or similar methods of display, but we had not settled on a good,bad,poor, or 1,2,3 etc.. system. Among criterion, I had not weighted any criterion as greater than any other - and I haven't personally found any compelling evidence to rank them otherwise. The only two I would consider for increased weight would be cost - given the cost containment focus of managed care - or perhaps equity - given the "minimum" quality threshold we are trying to impose for all plan members.

A final alternative to consider: We dropped Jeff's raising the reimbursement rate option, I think I remember opposing this for political feasibility's sake - and then I heard about New York's mandate for "risk adjusted" reimbursement rates that would force greater capitated fees or negotiated reimbursements for sicker individuals. Any thoughts on inclusion?? or justification for exclusion???

And last but not least - I thought I would mention that we should to settle on a manged care definition for continuity in presentation. I have been using the term broadly to apply to both HMO's, PPO's and everything in between - generally because cost containment efforts appear in all forms of health insurance that is not fee for service. If anyone has any objections otherwise - please let me know.

I am sure that at our next meeting we can air out these issues. I am looking forward to really nailing down both our threshold criteria and other criteria, and to really comparing and contrasting the different options. Perhaps we can get a feel for overheads as well.

Thanks all - see you tomorrow.

Chris

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:29-OCT-1996 09:45:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Content-disposition: inline

===== END ATTACHMENT 2 =====

===== ATTACHMENT 3 =====

ATT CREATION TIME/DATE:29-OCT-1996 09:45:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01IB7LICLIU0006DSA@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Tue, 29 Oct 1996 09:44:12 -0400 (EDT)

Received: from hcfa.gov (158.73.85.22) by STORM.EOP.GOV (PMDf V5.0-7 #6879)

id <01IB7MAIL5IU000080@STORM.EOP.GOV> for levi_j@a1.eop.gov; Tue,
29 Oct 1996 10:05:11 -0700 (MST)

Received: from HCFA-Message_Server by hcfa.gov with Novell_GroupWise; Tue,
29 Oct 1996 09:04:15 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 3 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:29-OCT-1996 17:09:56.28

SUBJECT: HRSA strikes again...

TO: Nancy-Ann E. Min (MIN_N) Autoforward to: Remote Addressee (Nancy A.
Min@eop@lngtwy@eopmrx) (OMB)
READ:NOT READ

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:30-OCT-1996 11:56:45.86

CC: Richard J. Turman (TURMAN_R) Autoforward to: Remote Addressee (Richard J.
Turman@EOP@LNGTWY@EOPMRX) (OMB)
READ:NOT READ

CC: William G. White (WHITE_W) (OMB)
READ:29-OCT-1996 17:10:13.08

TEXT:
Apparently, HRSA has sent award notices to the states and Title I
cities with their formula awards...without notifying the
Department's press office or any of the rest of us. We're working
to rectify this so that some notice is taken of this over the next
few days.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: DVanhoven@hcfa.gov@INET@EOPMRX

CREATION DATE/TIME:29-OCT-1996 09:44:00.00

SUBJECT: Pennsylvania -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:29-OCT-1996 10:04:13.34

TEXT:

Jeff--

We do not have a section 1115 waiver request from Pennsylvania, although I believe they are considering submitting one. Do you know if this is a 1915(b)? I will see what I can find out for you. Also, I want to make you aware of an issue that New York has raised during the negotiation process. I will talk to you soon.

>>> Jeffrey Levi <LEVI_J@a1.eop.gov> 10/24/96 02:06pm >>>

I have gotten some inquiries from folks in PA about the state waiver and whether HIV-relevant questions are being asked by HCFA

in its review. I know nothing about the waiver -- and what its status is -- can you help me out with this?

thanks.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:29-OCT-1996 09:45:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IB7LICLIUO006DSA@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Tue, 29 Oct 1996 09:44:26 -0400 (EDT)

Received: from hcfa.gov (158.73.85.22) by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01IB7MEO8DQW000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Tue,
29 Oct 1996 10:08:54 -0700 (MST)

Received: from HCFA-Message_Server by hcfa.gov with Novell_GroupWise; Tue,
29 Oct 1996 09:10:15 -0500

X-Mailer: Novell GroupWise 4.1

Content-disposition: inline

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:29-OCT-1996 11:36:39.59

SUBJECT: Attached is the conference code list

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:29-OCT-1996 11:52:19.59

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:29-OCT-1996 11:38:34.86

TO: Dennis Burke (BURKE_D) (OPD)
READ:29-OCT-1996 11:46:04.87

TO: Pamela Cicetti (CICETTI_P) (WHO)
READ:29-OCT-1996 11:36:57.16

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:29-OCT-1996 11:48:20.90

TO: Deborah L. Fine (FINE_D) (OPD)
READ:11-NOV-1996 16:51:26.28

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:29-OCT-1996 11:47:05.52

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:29-OCT-1996 15:00:21.53

TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ:29-OCT-1996 11:42:39.28

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:29-OCT-1996 12:02:23.47

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:29-OCT-1996 11:52:11.05

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:29-OCT-1996 11:52:06.94

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:29-OCT-1996 12:16:38.72

TO: Bruce N. Reed (REED_B) (WHO)
READ:29-OCT-1996 14:49:39.88

TO: Diane Regas (REGAS_D) (OPD)
READ:29-OCT-1996 11:36:48.75

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:29-OCT-1996 11:37:19.68

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:29-OCT-1996 11:42:33.26

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:29-OCT-1996 11:58:49.60

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:29-OCT-1996 13:29:21.45

TO: Michael Cohen (COHEN_M) (OPD)
READ:29-OCT-1996 12:27:20.75

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:29-OCT-1996 13:01:13.15

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:29-OCT-1996 14:23:41.18

TO: Claudia M. Rayford-Williams (RAYFORDWIL_C) (OPD)
READ:29-OCT-1996 12:20:43.23

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:29-OCT-1996 11:51:23.96

TO: Mia Masten (MASTEN_M) (OPD)
READ:30-OCT-1996 09:33:01.92

TEXT:
PRINTER FONT 14_POINT_COURIER
DPC CONFERENCE CALL CODES
FOR NOVEMBER 1996

PRINTER FONT 12_POINT_COURIER			
TUESDAY	WEDNESDAY	THURSDAY	FRIDAY
		Nov. 1	
		456	
-6777		code: 5678	
Nov. 5	Nov. 6	Nov. 7	Nov. 8
456			
-6777	456		
-6777	456		
-6777	456		
-6777			
code: 4433	code: 7297	code: 7297	code: 5577

Nov. 12 STAFF	Nov. 13 456	Nov. 14	Nov. 15
-6777	456		
-6777	456		
-6777 MEETING	code: 1395	code: 1395	code: 9900
Nov. 19 456	Nov. 20	Nov. 21	Nov. 22
-6777	456		
-6777	456		
-6777	456		
-6777 code: 2954	code: 6931	code: 6931	code: 4918
Nov. 26 456	Nov. 27	Nov. 28	Nov. 29
-6777	456		
-6777	HOLIDAY	456	
-6777 code: 7651	code: 8876		code: 3495

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:29-OCT-1996 11:06:43.84

SUBJECT: RE: From your past....

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:29-OCT-1996 11:52:04.36

TEXT:

How exciting for her!

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:29-OCT-1996 20:21:44.36

SUBJECT: RE: HIV and disability

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:30-OCT-1996 08:36:35.61

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:30-OCT-1996 10:11:06.81

CC: Molly Brostrom (BROSTROM_M) (WHO)
READ:30-OCT-1996 10:58:06.31

CC: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:30-OCT-1996 09:24:54.07

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:30-OCT-1996 11:56:13.96

CC: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:30-OCT-1996 08:41:41.58

TEXT:

Thanks, Jeff. I really appreciated the "let's don't reinvent the wheel" part as this is an enormous issue for a lot of folks.
Diana, would you please call me tomorrow between 11 and 1 or catch me before/after the 1 p.m. meeting we have to talk about the work/SSA issue and update me on where we are since last meeting with Ken.
Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:29-OCT-1996 15:01:42.54

SUBJECT: HIV and disability

TO: Carol H. Rasco (RASCO_C) (WHO)

READ:29-OCT-1996 15:21:31.73

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:29-OCT-1996 17:17:15.51

TO: Molly Brostrom (BROSTROM_M) (WHO)

READ:29-OCT-1996 15:07:19.44

TO: Diana M. Fortuna (FORTUNA_D) (OPD)

READ:30-OCT-1996 09:18:34.40

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:30-OCT-1996 11:57:04.95

TEXT:

PRINTER FONT 12_POINT_ROMAN

As Jeremy requested, this is some background on the meeting re HIV and disability policy Patsy mentioned at yesterday's staff meeting.

The meeting with SSA and HCFA was initiated by OMB, given their interest in determining HIV

-related costs in SSI, SSDI, and

Medicare. (Medicaid was the subject of a separate meeting.) It also reflected a hope that, with improvements in treatment, it might be possible to reduce some of the SSI and SSDI costs, if people are able to return to work. Thus, the meeting became something of a primer for us on how the system does not support those who want to try to return to work.

As follow up we are pursuing how to get a better handle on how many people with AIDS are in the Social Security and the Medicare systems. (Let's just say the current estimates are not based on hard data.) In addition, we will be talking with SSA about how they can work with the AIDS community to help AIDS service providers better understand the (limited) options available for people who do want to go back to work -- this is a new issue for the AIDS service organizations, and they are going to need some TA.

Finally, it might be good for all of us to talk about how we might integrate the HIV community into the larger discussions about encouraging a return to work. They bring some added political clout -- and they need to be discouraged from going off and recreating the wheel on their own as they "discover" this issue.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Nancy A. Min@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:29-OCT-1996 18:02:00.00

SUBJECT: Re: HRSA strikes again...

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:30-OCT-1996 09:24:13.14

TEXT:
Message Creation Date was at 29-OCT-1996 17:54:00

You have got to be kidding. Are they on Pluto or something?

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
007. email	From: Jeffrey Levi, To: Carol Rasco, Re: From Your Past.... [personal] [partial] (1 page)	10/29/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:29-OCT-1996 10:12:19.17

SUBJECT: From your past....

TO: Carol H. Rasco (RASCO_C) (WHO)

READ:29-OCT-1996 10:12:28.31

TEXT:

I had breakfast today with Kerry Lobel -- who had wonderful things to say about working with you in Arkansas. She has just been named executive director of the National Gay and Lesbian Task Force -- my old job in the late 80s. She seems quite good -- sensible, well grounded (b)(6)
(b)(6) I think she plans to be in touch with you after the election.

[007]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:29-OCT-1996 11:47:11.40

SUBJECT: Education message FYI

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:29-OCT-1996 11:57:34.82

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:29-OCT-1996 11:52:23.39

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:29-OCT-1996 12:12:30.28

TO: Dennis Burke (BURKE_D) (OPD)
READ:29-OCT-1996 11:52:16.43

TO: Diane Regas (REGAS_D) (OPD)
READ:29-OCT-1996 12:58:43.73

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:29-OCT-1996 14:24:00.95

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:29-OCT-1996 11:48:17.28

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:29-OCT-1996 15:00:26.75

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:29-OCT-1996 12:02:58.57

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:29-OCT-1996 11:52:28.40

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:29-OCT-1996 13:02:33.67

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:29-OCT-1996 12:12:38.80

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:29-OCT-1996 14:54:58.52

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:29-OCT-1996 11:58:56.56

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:29-OCT-1996 13:29:26.84

TO: Michael Cohen (COHEN_M) (OPD)
READ:29-OCT-1996 12:27:37.59

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:29-OCT-1996 12:02:07.33

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:29-OCT-1996 11:53:44.45

TEXT:

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:29-OCT-1996 11:35:00.00

ATT CREATOR: ACCOUNT, BEAUBAIRE_D1

ATT SUBJECT: EDUC-TP

ATT TO: Remote Addressee (SYLVIA.MATHEWS@TREAS.SPRINT.COM@INET)

ATT TO: Remote Addressee (SULLIVAN@OSDPO.SECDEF.OSD.MIL@INET)

ATT TO: Remote Addressee (HOGANJOH@JUSTICE.USDOJ.GOV@INET)

ATT TO: Remote Addressee (ANNE_SHIELDS@IOS.DOI.GOV@INET)

ATT TO: Remote Addressee (gfrazier@usda.gov@INET)

ATT TO: Remote Addressee (kthurm@os.dhhs.gov@INET)

ATT TO: Remote Addressee (ann_bormolini@postmaster2.dot.gov@INET)

ATT TO: Remote Addressee (frank_holleman@ed.gov@INET)

ATT TO: Chantale Wong (WONG_C)

ATT TO: Michelle M. Jolin (JOLIN_M)

ATT TO: Jennifer Palmieri (PALMIERI_J)

ATT TO: John C. Angell (ANGELL_J)

ATT TO: Barry J. Toiv (TOIV_B)

ATT TO: Martha Foley (FOLEY_M)

ATT TO: Janice A. Enright (ENRIGHT_J)

ATT TO: Patricia A. McHugh (MCHUGH_P)

ATT TO: Remote Addressee (jbullock@fema.gov@INET)

ATT TO: Thomas O'Donnell (ODONNELL_T)

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
--------------------------	---------------	------	-------------

008. email	From: Elizabeth Drye, To: Many Recipients, Re: Education Message FYI [partial] (1 page)	10/29/1996	P3/b(3)
------------	--	------------	---------

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

ATT TO: Elizabeth E. Drye (DRYE_E)

ATT TO: Remote Addressee (michael.cushing@opm.gov@INET)

ATT TO: Remote Addressee (b)(3)

ATT TO: Remote Addressee (brian.coyne@ssa.gov@INET)

[008]

ATT TO: Janet L. Crist (CRIST_J)

ATT TO: FAX (97364495,Thomas Donilon) (TLXA1MAIL_F:97364495\C:Thomas Donilon\\)

ATT TO: FAX (96471811,William Burns) (TLXA1MAIL_F:96471811\C:William Burns\\)

ATT TO: FAX (97367555,Elaine Shocas) (TLXA1MAIL_F:97367555\C:Elaine Shocas\\)

ATT TO: FAX (912124154029,Stuart Jones) (TLXA1MAIL_F:912124154029\C:Stuart Jones\\)

ATT TO: FAX (53390,Peter Scher) (TLXA1MAIL_F:53390\C:Peter Scher\\)

ATT TO: FAX (9260-0279,Peter Robertson) (TLXA1MAIL_F:9260-0279\C:Peter Robertson\\)

TEXT:

PRINTER FONT 12_POINT_ROMAN

Improving our Children's Educations,

Creating Opportunity for All

October 29, 1996

The strongest educational system in the world. President Clinton believes that education must be our highest priority as a nation, and is to preparing our people for a 21st century economy. Today, he has issued challenges to schools, businesses, teachers and communities to help raise standards so that every child can benefit.

A renewal of educational standards, for students, parents and schools. Education is about our values, and to meet the challenges of a global, highly-skilled, information economy, we must renew our educational system once again. President Clinton has called for:

- * An end to "social promotion", requiring students to pass tough tests to keep moving up in school;
- * Rewarding teachers who meet increased professional standards, and for removing those who don't;
- * Colleges and universities to look at admission requirements and make sure they are demanding excellence;
- * Every state and community to publish a report card for each public school, so parents can have the information they need to make well informed choices and help improve their own school. These report cards should be published in newspapers and on the Internet;
- * States and local communities to step in and fix schools that are persistently failing with respect to academic performance. If they cannot be fixed, the President challenged states to close these schools and reopen them as Charter schools -- schools that are formed by teachers and parents which are free of bureaucracy, and survive only if they produce results. This year, funding for the President's Charter Schools Initiative has almost tripled,

from \$18 million to \$51 million.

A long commitment to educational reform. President Clinton is committed to making sure every third-grader can read on their own, every eighth-grader can log onto the Internet, and every 18-year old can go on to college. Other initiatives and proposals include:

- * Make at least two years of college as universal as high school education is today, using targeted tax cuts to do it. The proposal includes a \$1,500 HOPE scholarship and a \$10,000 tax deduction to help middle class families afford the cost of higher education.
 - * Expand Head Start, Pell Grants, National Service, and College work study programs.
 - * Allow penalty-free withdrawals from IRAs for education expenses.
 - * Expand public school choice, especially through charter schools.
 - * Make every child technologically literate, with a \$2 billion Technology Literacy Challenge Fund to help connect more schools to the Internet.
 - * An expansion of the Safe and Drug Free Schools program.
 - * America's Reading Corps, which will provide tutoring for 3 million children who want and need help in order to read by themselves.
- President Clinton has proposed that we require 100,000 of our college students earning work study to take part in this effort.

* A GI Bill for America's workers, a \$2,600 grant for dislocated workers who need one, to return to school or get the training they need to make the most of their own lives.

* Improved direct lending, cutting the costs of loans for college students.

* \$1,000 college honors scholarships for the top 5% of students from every high school.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:30-OCT-1996 11:24:35.09

SUBJECT: RE: The future

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:30-OCT-1996 11:30:37.88

TEXT:

Re: your timeline....

Unfortunately after talking with folks here in COS office who are working on transition, I don't think we will be in a position to know by mid-November what our staffing patterns will be, etc. This is not a negative reflection on you but instead just caught in the transition process. I am VERY sorry about that and hope that if you do move on Dec. 1 that as things materialize around here we might come back to you if it looks like things will open up, we can reconfigure, etc. I really wish I had more answers now and/or had the authority to wave a wand and say: So be it...but alas, none of us outside the COS office are in a position to do that right now.

Sigh.....

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:30-OCT-1996 10:19:55.89

SUBJECT: RE: Pennsylvania -Reply

TO: Rachel Block (RBlock@hcfa.gov@INET@EOPMRX)

READ:NOT READ

TEXT:

don't have any of that...anything you can get me -- or we may be seeing each other Tuesday at the Whitman Walker meeting?

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Nancy A. Min@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:30-OCT-1996 11:57:00.00

SUBJECT: Re: HRSA

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:30-OCT-1996 12:25:40.76

TEXT:

Message Creation Date was at 30-OCT-1996 11:53:00

Sounds fine to me. Would you please just make sure we get a copy of the release?

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: LHARDY@OSASPE.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME:30-OCT-1996 09:31:00.00

SUBJECT: Mathematica study -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:30-OCT-1996 10:19:08.95

TEXT:

I spoke with HCFA's ORD and they agreed with us about need to have an HHS briefing before APHA. In fact, they noted that before results of HCFA-sponsored studies are released publicly, they tend to do this anyway.....but I'm glad we prompted them. I expect to hear something back today or tomorrow...Will let you know. Thanks for checking in.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:30-OCT-1996 09:32:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011B8ZDM8ZBK008TV2@PMDf.EOP.GOV> for LEVI_J@a1.eop.gov; Wed, 30 Oct 1996 09:31:27 -0400 (EDT)

Received: from OSASPE.DHHS.GOV by STORM.EOP.GOV (PMDf V5.0-7 #6879)

id <011B91CRUP6S000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed, 30 Oct 1996 10:28:02 -0700 (MST)

Received: from aspewise-Message_Server by OSASPE.DHHS.GOV with Novell_GroupWise; Wed, 30 Oct 1996 09:35:02 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: LHARDY@OSASPE.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME:30-OCT-1996 13:05:00.00

SUBJECT: Mathematica study -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:30-OCT-1996 13:22:49.71

TEXT:

I spoke with Steve Clauser (HCFA/ORD) earlier today, and he indicated that no data from Mathematica study would be presented at APHA...simply not ready yet. Will only present "methodology." I suggested that Steve call you directly to discuss further....so, if you haven't already, you should get a call from him. I also asked him to send any written info. they have describing the study's methodology.

I think they expect to have data from this study early in 1997....when they do, HCFA plans to conduct a briefing on these results before any public release (which is their typical practice).

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:30-OCT-1996 13:05:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IB96UMNGO000AS1T@PMD.F.EOP.GOV> for
LEVI_J@a1.eop.gov; Wed, 30 Oct 1996 13:05:12 -0400 (EDT)

Received: from OSASPE.DHHS.GOV by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01IB98TO9KSC000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed,
30 Oct 1996 14:01:46 -0700 (MST)

Received: from aspewise-Message_Server by OSASPE.DHHS.GOV with
Novell_GroupWise; Wed, 30 Oct 1996 13:08:41 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: RBlock@hcfa.gov@INET@EOPMRX

CREATION DATE/TIME:30-OCT-1996 09:47:00.00

SUBJECT: Pennsylvania -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:30-OCT-1996 10:19:26.96

TEXT:

Do you have the comments/issues paper they developed? I should probably also give you the HCFA questions and the State's responses (we asked a lot of questions suggested by the Law Project). Let me see if it's faxable...

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:30-OCT-1996 09:48:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011B8ZXU508000AJWJ@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Wed, 30 Oct 1996 09:47:45 -0400 (EDT)

Received: from hcfa.gov (158.73.85.22) by STORM.EOP.GOV (PMDf V5.0-7 #6879)
id <011B91X07C3I000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed,
30 Oct 1996 10:44:21 -0700 (MST)

Received: from HCFA-Message_Server by hcfa.gov with Novell_GroupWise; Wed,
30 Oct 1996 09:46:18 -0500

X-Mailer: Novell GroupWise 4.1

Content-disposition: inline

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Virginia A. Huth@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:30-OCT-1996 19:07:00.00

SUBJECT: Ryan White briefing

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:31-OCT-1996 12:07:59.63

TO: WHITE_WI (WHITE_WI@A1@CD) (WHO)
READ:31-OCT-1996 15:12:48.01

TEXT:
Message Creation Date was at 30-OCT-1996 19:03:00

Here is a proposed agenda to send over to HRSA in anticipation of our meeting next week. Please let me know what you think as soon as possible, but by COB Thursday, as the agency is waiting for us.

1. Brief overview of Titles I and II -- how it works.
2. What are the key data from this program and how has this data motivated management priorities to date? For example, how many people are being served? How many people get different kinds of services? How has the program ensured that client counts are unduplicated?
3. How do local programs use this data in planning and evaluation at the local level?
4. What are the main budget breakdowns, including monies spent on primary care, case management, support services, counselling, housing.
5. What are the proposed changes to the data collection and their justification?
6. Has HRSA discussed with grantees ways to collect more useful data?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:30-OCT-1996 11:06:24.30

SUBJECT: HRSA

TO: Nancy-Ann E. Min (MIN_N) Autoforward to: Remote Addressee
Min@eop@lngtwy@eopmrk) (OMB)
READ:NOT READ

(Nancy A.

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:30-OCT-1996 11:54:05.82

TEXT:

Now that we've been able to talk with HRSA...it turns out that states and cities were told their formula amounts if they actually submit applications...this is the technicality that kept them from doing the press release. On the other hand, if word is out that these funds are available, this is a good time to let the public know. Would you be comfortable with a press statement from the department or HRSA saying that states have been notified that they should apply for these funds...which gives us a chance to remind the world that there's another billion dollars going out for AIDS? This would also avoid any issues around challenges or complaints about the size of specific awards to specific states/cities.
Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:30-OCT-1996 09:24:04.00

SUBJECT: Mathematica study

TO: Remote Addressee (LESLIEH@OSASPE.SSW.DHHS.GOV@INET@EOPMRX)

READ:NOT READ

TEXT:

Any reaction yet about how to deal with the Mathematica study?

Just checking....thanks.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Gordon P. Agress@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:30-OCT-1996 18:13:00.00

SUBJECT: HIV/AIDS and Cities Meeting

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:31-OCT-1996 12:06:03.90

TO: Richard J. Turman (Richard J. Turman@EOP@LNGTWY@EOPMRX)
READ:NOT READ

TO: Wm G. White (Wm G. White@EOP@LNGTWY@EOPMRX)
READ:NOT READ

TO: Barbara A. Menard (Barbara A. Menard@EOP@LNGTWY@EOPMRX)
READ:NOT READ

TO: Margaret A. Murray (Margaret A. Murray@EOP@LNGTWY@EOPMRX)
READ:NOT READ

TEXT:
Message Creation Date was at 30-OCT-1996 18:08:00

Tomorrow's meeting on HHS's ideas for coordinating Federal HIV/AIDS funding and services in one or two cities will be held at 11 am in room 727E of the Humphrey building.

ASMB tells me that HHS will be represented by Eric Goosby, Deborah (from his staff), Robin Funston and perhaps Bill Beldon (these last two from ASMB). The agencies will not be at this meeting.

I told ASMB that our agenda was to learn what ideas HHS has, what funding they are talking about, how they would coordinate it, what their authorities are, etc.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Dorothy K. Craft (CRAFT_D) (OPD)

CREATION DATE/TIME:30-OCT-1996 12:25:18.88

SUBJECT: Goodbye Card

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:30-OCT-1996 17:16:58.58

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:30-OCT-1996 18:36:50.58

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:30-OCT-1996 12:46:35.84

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:30-OCT-1996 12:30:29.97

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:30-OCT-1996 13:01:36.29

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:30-OCT-1996 13:54:05.24

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:30-OCT-1996 13:59:41.62

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:30-OCT-1996 15:00:07.24

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:30-OCT-1996 13:59:21.62

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:30-OCT-1996 16:47:53.77

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:30-OCT-1996 12:25:59.88

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:30-OCT-1996 12:26:18.16

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:30-OCT-1996 12:31:16.24

TO: Dennis Burke (BURKE_D) (OPD)
READ:30-OCT-1996 14:24:24.89

TO: Mia Masten (MASTEN_M) (OPD)
READ:31-OCT-1996 11:35:24.24

TO: Diane Regas (REGAS_D) (OPD)
READ: 6-NOV-1996 15:13:31.35

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ: 30-OCT-1996 13:22:07.27

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ: 30-OCT-1996 12:25:36.11

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ: 30-OCT-1996 13:21:32.97

TO: Michael Cohen (COHEN_M) (OPD)
READ: 30-OCT-1996 12:30:45.73

TEXT:

Bernice, our volunteer who has been with the administration four full years on election day, is taking a six-month leave of absence. Please stop by my office and sign her card, if you can. The card is in the RED ENVELOPE on my desk. Thank you.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:30-OCT-1996 09:25:16.76

SUBJECT: Pennsylvania

TO: Remote Addressee (rblock@hcfa.gov@INET)

READ:NOT READ

TEXT:

my current plan is to join you....is there anything I need to know about the proposal that would be helpful for me to have before the meeting? Thanks.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: WESTMORT@WPGATE.LAW3.GEORGETOWN.EDU@INET@EOPMRX

CREATION DATE/TIME:30-OCT-1996 15:08:00.00

SUBJECT: fyi...wheels turn slowly.... -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:30-OCT-1996 15:14:00.47

TEXT:
So no data no Medicare at all?

Hmmm.

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:30-OCT-1996 15:09:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <011B9B5W523K00BCCD@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Wed, 30 Oct 1996 15:08:49 -0400 (EDT)
Received: from WPGATE.LAW3.GEORGETOWN.EDU by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <011B9D51USN4000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed,
30 Oct 1996 16:05:25 -0700 (MST)
Received: from LAWCAMPUS-Message_Server by WPGATE.LAW3.GEORGETOWN.EDU with
Novell_GroupWise; Wed, 30 Oct 1996 15:09:12 -0500
X-Mailer: Novell GroupWise 4.1
Content-disposition: inline
===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:30-OCT-1996 10:19:01.44

SUBJECT: RE: HIV and disability

TO: Diana M. Fortuna (FORTUNA_D) (OPD)

READ:30-OCT-1996 10:24:52.25

TEXT:

I can't make it today -- but why don't we find a time next week
for you to bring me up to speed...thanks

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:30-OCT-1996 13:23:56.53

SUBJECT: fyi...wheels turn slowly....

TO: Remote Addressee (WESTMORT@WPGATE.LAW3.GEORGETOWN.EDU@INET@EOPMRX)
READ:NOT READ

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:30-OCT-1996 14:04:00.00

ATT BODYPART TYPE:E

ATT CREATOR: LESLIE HARDY

ATT SUBJECT: Mathematica study -Reply

ATT TO: LEVI_J (LEVI_J@A1@CD)

TEXT:

I spoke with Steve Clauser (HCFA/ORD) earlier today, and he indicated that no data from Mathematica study would be presented at APHA...simply not ready yet. Will only present "methodology." I suggested that Steve call you directly to discuss further....so, if you haven't already, you should get a call from him. I also asked him to send any written info. they have describing the study's methodology.

I think they expect to have data from this study early in 1997....when they do, HCFA plans to conduct a briefing on these results before any public release (which is their typical practice).

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:30-OCT-1996 13:05:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <011B96UMNGO000AS1T@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Wed, 30 Oct 1996 13:05:12 -0400 (EDT)

Received: from OSASPE.DHHS.GOV by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <011B98TO9KSC000080@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed,
30 Oct 1996 14:01:46 -0700 (MST)

Received: from aspwise-Message_Server by OSASPE.DHHS.GOV with
Novell_GroupWise; Wed, 30 Oct 1996 13:08:41 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Diana M. Fortuna (FORTUNA_D) (OPD)

CREATION DATE/TIME:30-OCT-1996 09:30:58.61

SUBJECT: RE: HIV and disability

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:30-OCT-1996 10:18:09.29

CC: Carol H. Rasco (RASCO_C) (WHO)
READ:30-OCT-1996 09:48:54.85

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:30-OCT-1996 10:12:08.22

CC: Molly Brostrom (BROSTROM_M) (WHO)
READ:30-OCT-1996 10:58:21.83

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:30-OCT-1996 09:36:06.76

TEXT:

Thanks for the update. I am holding a weekly meeting (Wednesdays at 11) with SSA, HHS, Education, OMB to vet/advance some proposals on encouraging return to work. We hope to have a preliminary product at the end of November. Today's meeting is in Room 476 if you want to come. And I should brief you on our work to date.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:31-OCT-1996 14:11:34.97

SUBJECT: Agenda items needed

TO: Bruce N. Reed (REED_B) (WHO)
READ:31-OCT-1996 14:33:32.80

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:31-OCT-1996 14:29:38.75

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:31-OCT-1996 14:16:42.21

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:31-OCT-1996 14:18:02.61

TO: Dennis Burke (BURKE_D) (OPD)
READ:31-OCT-1996 14:35:59.80

TO: Michael Cohen (COHEN_M) (OPD)
READ:31-OCT-1996 14:46:14.73

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:31-OCT-1996 15:17:39.73

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:31-OCT-1996 15:46:31.48

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:31-OCT-1996 14:17:55.65

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:31-OCT-1996 17:01:19.70

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:31-OCT-1996 14:16:43.94

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:31-OCT-1996 16:11:32.73

TO: Diane Regas (REGAS_D) (OPD)
READ: 7-NOV-1996 10:09:59.79

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:31-OCT-1996 14:24:11.54

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:31-OCT-1996 15:55:14.31

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:31-OCT-1996 14:26:40.51

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:31-OCT-1996 14:24:52.48

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:31-OCT-1996 15:59:59.67

TEXT:

Olivia Golden and I have met a couple of times lately and found these one on one sessions quite helpful in facilitating communication between our offices. We will try to meet regularly every other week. My next meeting with her is Monday, Nov. 4 at noon.

You should each feel free to let me know of any items which you would like for me to bring up with her at our regular meetings.

Many thanks!

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:31-OCT-1996 12:07:39.61

SUBJECT: RE: Ryan White briefing

TO: Virginia A. Huth (Virginia A. Huth@EOP@LNGTWY@EOPMRX)
READ:NOT READ

CC: WHITE_WI (WHITE_WI@A1@CD) (WHO)
READ:NOT READ

TEXT:
looks good to me.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:31-OCT-1996 17:56:27.25

SUBJECT: In your absence

TO: Jennifer L. Klein (KLEIN_J) (OPD)

READ:31-OCT-1996 18:40:14.71

TEXT:

...with whom should we work re HIV issues in the First Lady's office -- and more particularly, about possibly doing something with grandparents (e.g., for world aids day?)???
thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:31-OCT-1996 12:09:40.92

SUBJECT: RE: Cabinet Affairs request

TO: Jill Pizzuto (PIZZUTO_J) (OPD)

READ:31-OCT-1996 12:28:49.43

TEXT:

count me in

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Sarah S. Freeman (FREEMAN_S) (WHO)

CREATION DATE/TIME:31-OCT-1996 16:57:54.64

SUBJECT: native americans

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:31-OCT-1996 17:11:04.99

TEXT:

I just got a lot more letters from Native American groups concerned about the decreased AIDS funding.

I have the draft you sent me, but it doesn't really work coming from the President (too specific).

I think the best way to handle this is to have a general letter from the President referring their letter to AIDS Policy and then you answer it with your draft. Let me know what you think.

thanks. Sarah

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:31-OCT-1996 11:50:42.73

SUBJECT: just an fyi

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:31-OCT-1996 14:21:08.25

TO: Molly Brostrom (BROSTROM_M) (WHO)

READ:31-OCT-1996 13:19:37.24

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)

READ:31-OCT-1996 13:06:06.13

TO: Dennis Burke (BURKE_D) (OPD)

READ:31-OCT-1996 11:52:30.39

TO: Dorothy K. Craft (CRAFT_D) (OPD)

READ:31-OCT-1996 13:21:20.85

TO: Michael Cohen (COHEN_M) (OPD)

READ:31-OCT-1996 14:31:46.78

TO: Elizabeth E. Drye (DRYE_E) (OPD)

READ:31-OCT-1996 14:00:56.77

TO: Deborah L. Fine (FINE_D) (OPD)

READ:11-NOV-1996 17:10:51.02

TO: Diana M. Fortuna (FORTUNA_D) (OPD)

READ:31-OCT-1996 12:13:45.30

TO: Lyndell Hogan (HOGAN_L) (OPD)

READ:31-OCT-1996 13:18:06.55

TO: Christopher C. Jennings (JENNINGS_C) (WHO)

READ:31-OCT-1996 16:20:48.07

TO: Jennifer L. Klein (KLEIN_J) (OPD)

READ:31-OCT-1996 12:26:49.50

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:31-OCT-1996 12:10:15.18

TO: Mia Masten (MASTEN_M) (OPD)

READ:31-OCT-1996 12:29:31.39

TO: Cathy R. Mays (MAYS_C) (OPD)

READ:31-OCT-1996 12:01:20.57

TO: Claudia M. Rayford-Williams (RAYFORDWIL_C) (OPD)
READ:31-OCT-1996 11:52:14.80

TO: Diane Regas (REGAS_D) (OPD)
READ: 7-NOV-1996 10:09:52.05

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:31-OCT-1996 12:05:08.68

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:31-OCT-1996 12:23:19.81

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:31-OCT-1996 12:27:18.91

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:31-OCT-1996 12:02:32.85

TEXT:

don't worry about getting back to me on whether or on not you will be going to
that 3:30, 11/6 welcoming event. they just called back and only need chr's
response.
thanks anyway.

looking forward to this day... moooooo, moooooo
(get it?)

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Patsy Fleming (FLEMING_P) (WHO)

CREATION DATE/TIME:31-OCT-1996 16:15:48.53

SUBJECT: Drug Pricing, etc.

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:31-OCT-1996 16:34:50.21

CC: Ursula Sanville (SANVILLE_U) (OPD)

READ:31-OCT-1996 17:18:53.26

TEXT:

Carol has asked that Eliz. Drye be included in all discussions regarding this issue because she has been working with FDA.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: LEVI_J@A1@CD (WHO)

CREATION DATE/TIME:31-OCT-1996 12:07:00.00

SUBJECT: RE: Ryan White briefing

TO: Virginia A. Huth (Virginia A. Huth@EOP@LNGTWY@EOPMRX)
READ:NOT READ

CC: WHITE_WI (WHITE_WI@A1@CD) (WHO)
READ:31-OCT-1996 15:20:43.37

TEXT:
looks good to me.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:31-OCT-1996 09:17:12.16

SUBJECT: see attached for hot issues deadlines.

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:NOT READ

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:31-OCT-1996 09:27:28.06

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:31-OCT-1996 09:29:12.31

TO: Dennis Burke (BURKE_D) (OPD)
READ:31-OCT-1996 09:17:41.85

TO: Diane Regas (REGAS_D) (OPD)
READ: 7-NOV-1996 10:09:25.84

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:31-OCT-1996 11:17:03.30

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:31-OCT-1996 09:27:49.39

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:31-OCT-1996 09:21:40.46

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:31-OCT-1996 12:25:28.86

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:31-OCT-1996 12:08:40.62

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:31-OCT-1996 10:10:24.96

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:31-OCT-1996 09:18:06.81

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:31-OCT-1996 10:48:08.46

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:31-OCT-1996 09:52:24.09

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:31-OCT-1996 09:18:03.10

TO: Michael Cohen (COHEN_M) (OPD)
READ:31-OCT-1996 11:01:07.48

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:31-OCT-1996 13:03:44.98

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:31-OCT-1996 09:51:47.20

TEXT:

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:31-OCT-1996 08:37:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Lyndell Hogan

ATT SUBJECT: morning call

ATT TO: Elizabeth E. Drye (DRYE_E)

TEXT:

Hot Issues up through Sunday due tomorrow (Friday) at noon.

--The new hot issues through Tuesday are:

Springfield, MA; Manchester, NH; Cleveland, OH; Lexington, KY; LA; Little Rock

--No amplification call Monday

--No weekly due tomorrow.

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
009. email	From: Jill Pizzuto, To: Many Recipients, Re: Kennedy Center Tickets for Nov. 6th (2 pages)	10/31/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[10/25/1996 - 11/01/1996]

2018-0759-F

jn437

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:31-OCT-1996 11:31:35.43

SUBJECT: Cabinet Affairs request

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:31-OCT-1996 14:20:42.28

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:31-OCT-1996 13:19:08.69

TO: Dennis Burke (BURKE_D) (OPD)
READ:31-OCT-1996 11:51:29.90

TO: Pamela Cicetti (CICETTI_P) (WHO)
READ:31-OCT-1996 11:32:16.65

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:31-OCT-1996 14:00:22.12

TO: Deborah L. Fine (FINE_D) (OPD)
READ: 6-NOV-1996 17:32:25.64

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:31-OCT-1996 12:13:08.79

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:31-OCT-1996 16:03:54.02

TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ:31-OCT-1996 13:20:53.54

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:31-OCT-1996 12:26:36.38

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:31-OCT-1996 12:10:02.17

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:31-OCT-1996 11:32:51.31

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:31-OCT-1996 12:00:58.75

TO: Bruce N. Reed (REED_B) (WHO)
READ:31-OCT-1996 12:51:06.48

TO: Diane Regas (REGAS_D) (OPD)
READ: 7-NOV-1996 10:09:41.49

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:31-OCT-1996 11:35:13.96

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:31-OCT-1996 12:02:20.92

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:31-OCT-1996 11:35:04.10

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:31-OCT-1996 12:11:30.43

TO: Michael Cohen (COHEN_M) (OPD)
READ:31-OCT-1996 11:50:49.79

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:31-OCT-1996 11:31:47.06

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:31-OCT-1996 11:31:47.11

TO: Claudia M. Rayford-Williams (RAYFORDWIL_C) (OPD)
READ:31-OCT-1996 11:51:41.17

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ:31-OCT-1996 12:03:59.91

TO: Mia Masten (MASTEN_M) (OPD)
READ:31-OCT-1996 11:34:19.40

TEXT:

Cabinet Affairs called and is trying to get a head count on staff regarding attendance for the Nov. 6th Welcome Home event at 3:30p.
At this point, I believe it's just pass holders & campaign folks (not interns).
please respond to me asap so that I can get back to them.
thanks!

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jennifer L. Klein (KLEIN_J) (OPD)

CREATION DATE/TIME:31-OCT-1996 18:40:12.27

SUBJECT: RE: In your absence

TO: Jeffrey Levi (LEVI_J) (WHO)

READ: 1-NOV-1996 08:33:54.05

TEXT:

Pauline Abernathy and Nicole Rabner are filling in for me while I am gone. You can talk to either of them. I have let them know that you are my contact on AIDS (although I didn't tell them that you are leaving at some point).

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:31-OCT-1996 12:32:40.41

SUBJECT: Presidential Advisory Council

TO: Remote Addressee (dparham@hrsa.ssw.dhhs.gov@INET)
READ:NOT READ

TEXT:

Deborah:

The Presidential Advisory Council is meeting December 16 and 17th;
during one of those days, the prisons subcommittee, which Patricia
Milon is working with, will be meeting. Can we beg for Patricia's
time that day -- in addition to her regular Thursday time with
us?

Thanks very much.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: POSTMASTER@A1@CD

CREATION DATE/TIME:31-OCT-1996 12:07:00.00

SUBJECT: Auto reply from WHITE_WI

TO: LEVI_J@A1 (WHO)

READ:31-OCT-1996 12:10:47.49

TEXT:

I'll be on leave until November 5th. If you need assistance, you can contact Craig Gardenswartz (OPL) at 6-5170, or I can be reached in Nashville, TN at 615-329-2001.

Is this hi-tech or what!!

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:31-OCT-1996 12:11:35.38

SUBJECT: I think she sent this to the other William White

TO: William G. White (WHITE_W) (OMB)

READ:31-OCT-1996 12:11:47.66

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:30-OCT-1996 19:03:00.00

ATT BODYPART TYPE:E

ATT CREATOR: Virginia A. Huth

ATT SUBJECT: Ryan White briefing

ATT TO: LEVI_J (LEVI_J@A1@CD)

ATT TO: WHITE_WI (WHITE_WI@A1@CD)

TEXT:

Message Creation Date was at 30-OCT-1996 19:03:00

Here is a proposed agenda to send over to HRSA in anticipation of our meeting next week. Please let me know what you think as soon as possible, but by COB Thursday, as the agency is waiting for us.

1. Brief overview of Titles I and II -- how it works.
2. What are the key data from this program and how has this data motivated management priorities to date? For example, how many people are being served? How many people get different kinds of services? How has the program ensured that client counts are unduplicated?
3. How do local programs use this data in planning and evaluation at the local level?
4. What are the main budget breakdowns, including monies spent on primary care, case management, support services, counselling, housing.
5. What are the proposed changes to the data collection and their justification?
6. Has HRSA discussed with grantees ways to collect more useful data?

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:31-OCT-1996 17:29:25.52

SUBJECT: RE: native americans

TO: Sarah S. Freeman (FREEMAN_S) (WHO)

READ:31-OCT-1996 17:29:41.38

TEXT:

that's fine...send 'em over.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: LHARDY@OSASPE.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME: 1-NOV-1996 11:55:00.00

SUBJECT: Mathematica study -Reply

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ: 1-NOV-1996 12:53:40.66

TEXT:

Jeff: Just checking to see if you spoke with Steve Clauser about this study...and if everything is resolved at this point. I didn't hear anything further...and was just wondering.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE: 1-NOV-1996 11:58:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011BBWZNQ8KW00FYNX@PMDf.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 01 Nov 1996 11:55:18 -0400 (EDT)

Received: from OSASPE.DHHS.GOV by STORM.EOP.GOV (PMDf V5.0-7 #6879)

id <011BBWXHC95M000082@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 01 Nov 1996 11:53:36 -0700 (MST)

Received: from aspewise-Message_Server by OSASPE.DHHS.GOV with Novell_GroupWise; Fri, 01 Nov 1996 11:59:00 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)

CREATION DATE/TIME: 1-NOV-1996 11:45:48.81

SUBJECT: Reminder for weekly-- please get anything you want included

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ: 3-NOV-1996 13:34:07.08

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ: NOT READ

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ: 1-NOV-1996 11:47:05.00

TO: Dennis Burke (BURKE_D) (OPD)
READ: 1-NOV-1996 11:52:56.03

TO: Diane Regas (REGAS_D) (OPD)
READ: 7-NOV-1996 10:11:22.59

TO: Patsy Fleming (FLEMING_P) (WHO)
READ: 1-NOV-1996 12:56:22.43

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ: 1-NOV-1996 12:40:58.19

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ: 1-NOV-1996 16:19:21.18

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ: 1-NOV-1996 12:35:22.58

TO: Jeffrey Levi (LEVI_J) (WHO)
READ: 1-NOV-1996 12:53:34.06

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ: 1-NOV-1996 12:00:57.44

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ: 1-NOV-1996 11:45:55.52

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ: 1-NOV-1996 12:03:37.63

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ: 1-NOV-1996 11:45:55.64

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ: 5-NOV-1996 12:42:29.62

TO: Michael Cohen (COHEN_M) (OPD)
READ: 1-NOV-1996 11:57:03.22

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ: NOT READ

TEXT:
in to me by 1:00pm. Thanks!!

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: LHARDY@OSASPE.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME: 1-NOV-1996 13:48:00.00

SUBJECT: Re: Mathematica study -Reply -Reply

TO: LEVI_J (LEVI_J@AI@CD) (WHO)

READ: 1-NOV-1996 14:04:29.43

TEXT:

Sure, that would be fine. His number is 410-786-6504. I gave him yours in case he wanted to call you.

In any event, I expect he'll tell you what he told me-- that no data from this study will be presented at APHA (data aren't ready yet)...Steve said it's to be a "methodological " presentation...i.e., only study methodology to be presented and the challenges that have been confronted in collecting and analyzing data. I asked if he would send me a write-up of the methodology, but haven't received one yet.

Please call or email, if we can facilitate further at this end. By the way, I shared above info. with Meg at OMB.

>>> Jeffrey Levi <LEVI_J@a1.eop.gov> 11/01/96 11:53am >>>
didn't hear from him...do you want me to call him?

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE: 1-NOV-1996 13:48:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01IBC0XKPOLS00GWVV@PMDf.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 01 Nov 1996 13:48:10 -0400 (EDT)

Received: from OSASPE.DHHS.GOV by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <01IBC0VYYMXC000082@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 01 Nov 1996 13:46:56 -0700 (MST)

Received: from aspewise-Message_Server by OSASPE.DHHS.GOV with Novell_GroupWise; Fri, 01 Nov 1996 13:52:25 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME: 1-NOV-1996 16:41:24.15

SUBJECT: Rasco Longterm schedule

TO: David S. Beaubaire (BEAUBAIRE_D) (WHO)
READ: NOT READ

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ: 7-NOV-1996 09:16:32.00

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ: 5-NOV-1996 09:19:47.60

TO: Dennis Burke (BURKE_D) (OPD)
READ: 1-NOV-1996 17:46:41.60

TO: Pamela Cicetti (CICETTI_P) (WHO)
READ: 1-NOV-1996 16:41:55.70

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ: 3-NOV-1996 13:35:46.40

TO: Deborah L. Fine (FINE_D) (OPD)
READ: 11-NOV-1996 17:14:27.74

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ: 1-NOV-1996 16:48:10.58

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ: 5-NOV-1996 10:19:55.87

TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ: 4-NOV-1996 08:16:28.89

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ: 1-NOV-1996 17:33:07.73

TO: Jeffrey Levi (LEVI_J) (WHO)
READ: 1-NOV-1996 16:42:13.43

TO: Cathy R. Mays (MAYS_C) (OPD)
READ: 13-NOV-1996 11:00:54.50

TO: Carol H. Rasco (RASCO_C) (WHO)
READ: 2-NOV-1996 12:00:31.29

TO: Bruce N. Reed (REED_B) (WHO)
READ: 1-NOV-1996 16:41:30.28

TO: Diane Regas (REGAS_D) (OPD)
READ: 6-NOV-1996 15:13:10.29

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ: 1-NOV-1996 16:45:30.18

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ: 1-NOV-1996 16:55:01.44

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ: 1-NOV-1996 16:49:39.67

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ: 5-NOV-1996 12:43:35.43

TO: Michael Cohen (COHEN_M) (OPD)
READ: 4-NOV-1996 10:03:04.04

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ: 1-NOV-1996 16:45:33.44

TO: Patsy Fleming (FLEMING_P) (WHO)
READ: 1-NOV-1996 17:10:57.66

TO: Claudia M. Rayford-Williams (RAYFORDWIL_C) (OPD)
READ: 4-NOV-1996 10:03:26.99

TO: Leanne A. Shimabukuro (SHIMABUKUR_L) (OPD)
READ: 1-NOV-1996 16:50:22.47

TO: Mia Masten (MASTEN_M) (OPD)
READ: 12-NOV-1996 10:01:34.86

TEXT:

PRINTER FONT 12_POINT_ROMAN

TO: DPC STAFF

FR: JILL PIZZUTO

RE: CHR CALENDAR HIGHLIGHTS

Nov. 4:

12:30p Olivia Golden meeting

Nov. 5:

4:30p Cabinet arrives LR

Nov. 6:

3:30p Staff Welcome Home event

6:30p Clinton/Gore Finance Celebration

Nov. 7:

8:30a

-4:00p Welfare

-to

-Work Programs & Substance Abuse Seminar
/DC

Nov. 8:

10:00 Child Welfare meeting

5:00p Cabinet Affairs Meeting w/ the POTUS

Nov. 12:

5:30p Farewell to Larry Elworth, RM 211

Nov. 13:

10:00a Crime weekly meeting

11:00a Immigration weekly meeting

1:00p NGA/APWA/NCSL & interagencies meeting

3:30p J. David Hawkins, Ph.D/Univ. of Washington

Nov. 14:

Depart for Corpus Christi, Texas

12:31p Depart National

5:45p Arrive Corpus Christi

Nov. 15:

Corpus Christi, Texas

Texas A&M Dedication of the Early Childhood Development Center

pm Depart for LR

8:38p Arrive LR

Nov. 16

-21:

Personal / Little Rock

Nov. 21:

9:10p Arrive National

Nov. 25:

6:30p TENT Partnerships for Stronger Families/ Secretaries
meeting

Nov. 26:

6:30p TENT Partnerships for Stronger Families / Secretaries
meeting

Dec. 2:

3:30p Watson Bell (Chris Jennings to staff)

5:00p Cabinet meeting re: Welfare Reform

Dec. 3:

1:00p Child Welfare meeting

5:00p Partnership Conference / reception

Dec. 4:

8:30a

-4:00p Partnerships Conference

1:00p NGA/APWA/NCSL & agencies weekly meeting

6:30p TAPING /"Self Determination" - one hour panel
discussion w/ Bob Enteen

Nationally syndicated audio program

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME: 1-NOV-1996 12:53:59.09

SUBJECT: RE: Mathematica study -Reply

TO: LESLIE HARDY (LHARDY@OSASPE.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
didn't hear from him...do you want me to call him?

**Clinton Presidential Records
Automated Records Management System
[EMAIL] and Tape Restoration Project [Email]**

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies a responsive email, already made available within another collection.

Collection: 2013-0365-F

Bucket: WHO

Creation Date: 1996-11-01

Subject: tickler update

Creator: Jill Pizzuto PIZZUTO_J OPD

[illegible]

M:6JN<RZ`@(!&;W\*`=&AE@!U<G!O<V5S@&]F@!1H:7//86YA;'ES:7,L@&UA
M;F%G962`8V%R98!I;7!L:65S@&%N>8!F;W)M@&]F@&AE86QT:(!P;&%N@&9I
M;F%N8VEN9X!T:&%T@&1I9F9E<G.'9G)O;8!S=)I8W2`9F5EA&9O<H2\<V5R
M=FEC98!P;&%N<RR`86YD@%'U86QI='F`8V%R98!M96%N<X!P<F]V:61I;F>`
M=&AE@&YE8V5S<V%R>8!D:6%G;F]S=&EC@!IE<WIS@&%N9(!T<F5A=&UE;G1S
MSW1H872`86QR96%D>8!A<F6':VYO=VZ`=&^';&5A9(!T;X!G;V]D@&AE86QT
M:(!O=71C;VUE<X!A;F2`=&AA=(!A;'-O@!'-A=&ES9GF`<&%T:65N=(!E>!E
M8W1A=&EO;G,N@,]=6%L:71Y@&1I9F9E<F5N8V5S@&)E='E96Z`;6%N86=E
M9(!C87)E@&%N9(!F966`9F]R@!'-E<G9I8V6':&5A;'1H@&EN<W5R86YC98!P
M;&%N<X!C86[/<)O8F%B;F`8F6`871T<FEB=71E9(!T;X!T=V^`87-P96-T
M<X!O9H!M86YA9V5D@&-A<F4Z@!1H98!;F-E;G1I=F5S@&9O<H!C;W-T@&-O
M;G1A:6YM96YTSW!R;W9I9&5D@&)Y@&UA;F%G962`8V%R98!A;F2`=&AE@)E
M<W1R:6-T:6JN@&]F@&UA<FME=(!O=71L970L@&4N9RZ`=&AE@!A=&EE;G2`
M:&%S@&YO@&-H;VEC9<]A;6JN9X!P;&%N<X!O<H!D;V-T;W)S@!IO@&-O=6YT
M97*`8F%L86YC98!F875L='F`<V5R=FEC92[,S,Q"+H!4:&6;@%!R;V)L96V`
M=VET:(!T:&6`4W1A='S@&%%U;S,5&AE<F6`:7.`6YC<F5A<VEN9X!P=6)L
M:6.`9&5B871E@&%B;W5T@!1H98!A<!A<F5N=(!D:7-P87)I='F`8F5T=V5E
M;H!T:&6`<75A;&ET>8!O9H!H96%L=&B`8V%R9<]O9F9E<F5D@&)Y@&UA;F%G
M962`8V%R98!P<F]G<F%M<X!A;F2`=)A9&ET:6JN86R`9F5E+69O<BUS97)V
M:6-E@!L86YS+H""07=A<F5N97-S@&]F@!1H:7//9&ES<&%R:71Y@&EN@&AE
M86QT:(!O=71C;VUE<X!A;F2`<&%T:65N=(!S871I<V9A8W1I;VZ`:&%S@&=R
M;W=N@&%S@&UO<F6`86YD@&UO<F6`<&5O<&QE@&9I;F3/= &AE;7-E;'9E<X!!
M;H!M86YA9V5D@&-A<F6';W)G86YI>F%T:6JN<RZ`@\$AE:6=H=&5N962`<5B
M;&EC@!R97-S=7)E@!IO@&%D9)E<W.`=&AE@&ES<W5ESW)E<W5L=&5D@&EN
M@!-I9VYI9FEC86YT@!-T871E@&QE9VES;&%T:6JN@&%N9(!C86QL<X!F;W*`
M9F5D97)A;(!A='IE;G1I;VXN@,S,5VAA=(!D;X!W98!M96%N@&)Y@&UA;F%G
M962`8V%R93^^@%=E@&%R98!E<W-E;G1I86QL>8!T86QK:6YG@&%B;W5T@&%N
M@&%P<)O86-H@!1H872`8VAA;F=E<]B;W1H@!1H98!F:6YA;F-I86R`97%U
M871I;VZ`8F5T=V5E;H!P<F]V:61E<H!A;F2`8V]N<W5M97*`86YD@!A=&EE
M;G2`;6%N86=E;65N="Z`@%5N9&5R@&/'=)A9&ET:6JN86R`9F5E+69O<BUS
M97)V:6-E@!L86XL@!R;W9I9&5R<X!A<F6`<F5I;6)U<G-E9(!B87-E9(!O
M;H!T:&6`<V5R=FEC97.`=&AE>8!P<F]V:61E+H#/2&]W979E<BR`=6YD97\*`
MG'-O;66;@&UA;F%G962`8V%R98!P;&%N<RR`G&5S<&5C:6%L;'F`=&AO<V6`
M<V5R=FEN9X!-961I8V%6I9(!B96YE9FEC:6%R:65S+`-#%0`""P)`""G+#<H
M.@`!(!4`T&AE86QT:)N`<&QA;G.`;V9F97*`<)O=FED97)S@&&`9FQA=(!F
M966`+2V`VYO=VZ`87.`88!C87!I=&%T962`<F%T98`M+8!T;X!P<F]V:61E
M@&9O<H!A;&R`=&AE@&-A<F6`86[/:6YD:79I9'5A;(!M:6=H=(!N965D+H""
MG\$]T:&5R@&9O<FUS@&]F@&UA;F%G962`8V%R99N`;V9F97*`<)O=FED97)S
M@&QO=X!N96=O=&EA=&5DSW)E:6UB=7)S96UE;G2`<F%T97,L@&)U=(!R97%U
M:7)E@!H>7-I8VEA;G.`=&^`<F5C96EV98!A<!R;W9A;(!F;W*`<W!E8VEA
M;'1Y@)E9F5R<F%L@&%N9(!O=&AE<L]P<F]C961U<F5S@("S@!1H:7.`:7.`
M8V%L;&5D@!5T:6QI>F%T:6JN@)E=FEE=RZ`@SEN@!1H98!L871T97\*`'=O
M@&9O<FUS@&]F@&AE86QT:(!C87)E+(!P<F]V:61E<G//96ET:&5R@&AA=F6`
M88!D:7)E8W2`:6YC96YT:79E@!IO@&AO;&2`9&]W;H!P871I96YT@&-O<WIS
M@!IO@&ME97"";6J]R98!O9H!T:&6`8V%P:71A=&5D@!A>6UE;G0LSV]R@!1H
M98!H96%L=&B`<&QA;H!I='-E;&:<V5T<X!U<(!M971H;V1S@!-U8VB`87.`
M=71I;&EZ871I;VZ`<F5V:65W@!IO@)QE<VYU<F6`=&AE@&YE8V5S<VET>8!O
M9IO/G!R97-C<FEB962;@)QC87)E+IN`S,Q(;W=E=F5R+(!M86YA9V5D@&-A
M<F6`86QS;X!S=)E86UL:6YE<X!P871I96YT<X!M86YA9V5M96YT@&)Y@&]F
M9F5R:6YG@&UO<F6`8V]O<F1I;F%T963/8V%R98!T:&%N@&9E98!F;W\*`<V5R
M=FEC98!P;&%N<RZ`@%5N9&5R@!1R861I=&EO;F%L@&AE86QT:(!P;&%N<RR`
M;F^';VYE@!H>7-I8VEA;H!O<H!G<F]U<(!O9L]P:'ES:6-I86YS@&UA;F%G
M962`86Z`:6YD:79I9'5A;/'<!/!S@&AE86QT:(!C87)E+H""36%N86=E9(!C
M87)E@&-O;W)D:6YA=&5S@&%N@&EN9&EV:61U86SP`3P<X!C87)ESW1H<F]U

M9VB`88!S:6YG;&6`<')I;6%R>8!C87)E@'!R;W9I9&5R+H'"5VET:(!A@'-I
M;F=L98!P:'ES:6-186Z`<F5S<&]N<VEB;&6`9F]R@&%N@&EN9&EV:6!U86SP
M"3P<\]M96!I8V%L@&UA;F%G96UE;G0L@'!H98!H96%L=&B`<&QA;H!A;F2`
M<&AY<VEC:6%N@&-A;H!B97!T97*`<')O=FED98!P<F5V96YT87!I=F6`8V%R
M98!A;F3/<W!E8VEA;'!Y@&-A<F6`=&%I;&]R962`=&^':6YD:79I9'5A;(!N
M965D<RZ`@,S,36%N86=E9(!C87)E@&AA<X!E;&EM:6YA=&5D@'-O;66`86-K
M;F]W;&5D9V5D@'5N;F5C97-S87)Y@&UE9&EC86R`8V%R98!A;F2`8V]N=&%I
M;F5DSVAE86QT:(!C87)E@&5X<&5N9&ET=7)E<RR`G!H<F]JU9VB`9FEN86YC
M:6%LFX!!;F-E;G!I=F5S@&%N9("=&AE@&-A<F5F=6R;@'-C<G5T:6YY@&]F
M@)QP<F5S8W)I8F5DF\]S97)V:6-E<RZ`@)Q-86YA9V5DFX!C87)E@&%D=F]C
M87!E@%!A=6R`!6QL=V]O9("=<F5C96YT;'F`86-K;F]W;&5D9V5DFX!T:&%T
M@)QM86YA9V5D@&-A<F6`:&%SSW)E;6]V962`86QL@&UE9&EC86R;@)QE>&-E
M<W,L@&%N9(!T:&%T@&%D9&ET:6]N86R`8W5T<X!C;W5L9(!H=7)T@'%U86QI
M='DN@(!-86YA9V5D@&-A<F6`86QS;]E;7!H87-I>F5S@&UO<F6`8V]O<F!I
M;F%T962`8V%R98!T')O=6=H@'!H98!U<V6`;V:`88!P<FEM87)Y@&-A<F6`
M<&AY<VEC:6%N+H'"08!S:6YG;&7/<&AY<VEC:6%N@&UA>8!B98!B97!T97*`
M86)L98!T;X!C;V]R9&EN87!E@&-A<F4L@'!H:7.`&5A;'!H@&-A<F6`9&5L
M:79E<GF`<W!R=6-T=7)E@&%L<V^';&EM:7!S@&%NSVEN9&EV:6!U86SP"3P
M<X!C:&]I8V6`86UO;F>`<')O=FED97)S+H'"26Z`<VAO<G0L@&%D9&ET:6]N
M86R`8V]S=(!S879!F=S@'5N9&5R@&UA;F%G962`8V%R98!M87G/8V]M<')O
M;6ES98!T:&6`<75A;&ET>8!O9H!H96%L=&B`8V%R98!P<F]V:6!E9"Z`S,Q-
M86YA9V5D@&-A<F6`9&5F:6YI=&5L>8!H87.`8V]N=')I8G5T962`=&^`=&AE
M@)E8V5N=(!L979E;&EN9X!O9H!H96%L=&B`8V%R98!E>'!E;F!I='5R97,N
M@("0<]R96-E;G2;@)Q+4\$U@'@'-U<G9E>8!O9H!E;7!L;WEE<G.`;F]T962;
M@'!H872`:&5A;'!H@&EN<W5R86YC98!P<F5M:75M<X!R;W-E@&]N;'F`,"XU
M)<^<8V]M<&%R962;@'!O@#(N,26`6Z`3DY-8!A;F2`-"XX)8!I;H`Q.3DT
M@&%N9(!T:&%T@'!H:7.`=V%S@'!H98!F:7)S=(!Y96%R@'=I=&B`;6]R9<]E
M;7!L;WEE97.`96YR;VQL962`6Z`2\$U!P\$V.`=&AA;H!F966`9F]R@'-E
M<G9I8V6`<&QA;G,N@(!;'!H;W5G:(!T:&6`6YD=7-T<GF`:&%SSV!E;6]N
M<W!R87!E9(!S=6-C97-S9G5L@&-O<W2`8V]N=&%I;FUE;G0L@(!M86YY@&AA
M=F6`8VAA<F=E9(!T:&%T@'!H97-E@&!E;6]N<W!R87!I;VYS@'!E;F2`=&_
M;V-C=7*`6Z`6%N86=E9(!C87)E@'!L86YS@'!H872`9&^';F]T@'-E<G9E
M@'!H;W-E@'!O<5L87!I;VYS@&YE96!I;F>`=&AE@&UO<W2`8V%R92Z`!F]R
MT`,5""+'D"><L-R@Z`\$@%0#097AA;7!L92R`9&5M;VYS=')A=&EO;H!P
M<F]G<F%M<X!P=7!T:6YG@\$UE9&EC86ED@&-L:65N='.`6YT;X!M86YA9V5D
M@&-A<F6`:&%V98!U<W5A;&QYSV5X8VQU9&5D@'!H;W-E@'=I=&B`9&ES86)I
M;&ET:65S+H""S,Q";W!H@&)U<VEN97-S97.`86YD@&=O=F5R;FUE;G2`96YT
M:7!I97.`:&%V98!O<&5N;'F`96UB<F%C962`;6%N86=E9(!C87)E@&%S@&&`
M=V%Y@'!OSV-O;G!A:6Z`:&5A;'!H@&5X<&5N9&ET=7)E<RZ`@\$EN@'!H98!E
M87)L>8`Q.3DP)W.`:&5A;'!H@&EN<W5R86YC98!I;F9L87!I;VZ`<F5A8VAE
M9(!D;W5B;&6`9&EG:7!S+;JJ=7-T@&%S@%4N4RZ`8V]M<&%N:65S@'=E<F6`
M8V]M:6YG@'5N9&5R@&EN8W)E87-I;F>`9VQO8F%L@&-O;7!E=&ET:6]N+H""
M5&AE@&)U<VEN97-SSV-O;6UU;FET>8!L;V]K962`=&^';6%N86=E9(!C87)E
M@)QT;X!H96QP@&-A<(!H96%L=&B`8V]S='NFX!4:&6`;G5M8F5R@&]F@'!E
M;W!L98!I;H!M86YA9V5DSV-A<F6`:&%S@&EN8W)E87-E9(!D<F%M87!I8V%L
M;'F';W9E<H!T:&6`;&%S=(!S979E<F%L@'EE87)S+H'"26Z`3DY,2R`-#<E
M@&]F@'!H;W-E@'=I=&C/96UP;&]Y;65N=(!B87-E9(!I;G-U<F%N8V6`=V5R
M98!I;H!S;VUE@&9O<FV`;V:`6%N86=E9(!C87)E.X!I;H`Q.3DT@'!H872`
M:6YC<F5A<V5D@'!OSS8U)2Z`@%-I;6EL87)L>2R`<W!A=&6`9V]V97)N;65N
M='.`;W!E<F%T:6YG@'5N9&5R@&)A;&%N8V5D@&)U9&=E=(!R97%U:7)E;65N
M='.`:&%D@'!O@&9I;F3/<V]M98!W87F`=&^`8V]N=')O;(!M96!I8V%L@&-O
M<W!S+H""5&AE@&UA:F]R:7!Y@&]F@'-T87!E<X!H879E@)E8V5I=F5D@&&`
M365D:6-A:62`=V%I=F5RSV9R;VV`G!H98!\$97!A<G!M96YT@&]F@\$AE86QT
M:(!A;F2`2'5M86Z`FU-E<G9I8V5S@'!O@'!L86-E@'-O;66`;V:`=&AE:7*`

M365D:6-A:62'<&]P=6QA=&EO;L]I;H!M86YA9V5D@&-A<F4N@\$UE9&EC86ED
M@&UA;F%G962'8V%R98!E;G)O;&QM96YT@&=R97>'9G)O;8'Q-"6':6Z'G#\$Y
M.3,L@'1OFX'R,R6':6Z',3DY-"S/G&%N9('S-26;@&EN@#\$Y.34N@('"26Z'
M861D:71I;VXL@\$UE9&EC87)E@&%L<V^':&%S@&)E9W5N@&5N<F]L;&EN9X!B
M96YE9FEC:6%R:65S@&EN=&^';6%N86=E9,]C87)E@'!L86YS@&%T@#DU)8!O
M9H"<=')A9&ET:6]N86R'9F5EA&9O<H!S97)V:6-EFX!C;W-T<RZ'S,Q-86YA
M9V5D@&-A<F6'9&]E<X!C;VYT86EN@&-O<W!S@'=E;&PL@'!H98!S;W5R8V6'
M9F]R@&ET<X!W:6!E<W!R96%D@'!O<5L87)I='DL@&)U=(!S979E<F%LSW)E
M8V5N=(!S='5D:65S@&AA=F6'8V]N9FER;65D@&=R;W=I;F>'86YE8V!O=&%L
M@&5V:6!E;F-E@'!H872';6%N86=E9(!C87)E@'!L86YS@&!O@&YO=,]P<F]V
M:6!E@'%U86QI='F'8V%R98!F;W* '<VEC:V5R@'!O<5L87!I;VYS@')E<75I
M<FEN9X!S<&5C:6%L:7!E9(!C87)E+H'"3&%S=(!M;VYT:(!T:&6'<)E<W//
M:&EG:&QI9VAT962'=&AE@')E<W5L='';V:'=&AE@\$UE9&EC86R'3W5T8V]M
M97.'4W!U9'F'<5B;&ES:&5D@&EN@)Q4:&6'2F]U<FYA;(!O9H!T:&6'06UE
M<FEC86[/365D:6-A;(!<W-O8VEA=&EO;H'H2D%-02DNFX'"5&AI<X!S='5D
M>8!F;W5N9(!S:6=N:69!8V%N=&QY@&QO=V5R@'!H>7-!8V%L@&%N9(!M96YT
M86R':&5A;'!HSV]U=&-O;65S@&%M;VYG@'!H98!P;V]R@&%N9(!E;&!E<FQY
M@&5N<F]L;&5D@&EN@&UA;F%G962'8V%R98#R"/)V<R[S"/.'9F5E@&9O<H!S
M97)V:6-E@&AE86QT:(!P;&%N<RZ'T'\$5''+'D''<\A'QTJ''\$@%0#0G%R
M96QI;6EN87)Y@')E<W5L='';V:'88!-96!18V%R98!S='5D>8!O9H!M86YA
M9V5D@&-A<F6'9F]R@&!I86)E=&5S@&9O=6YD@&5V96Z'=&AE@&)E<W3/2\$U/
M!P\$'.';&%C:VEN9RZ'@%N;W!H97*;'@'=!9&5L>8!P=6)L:6-I>F5D@'-T
M=6!Y@&)Y@'!H98!#;VUM;VYW96%L=&B'9G5N9(!F;W5N9(!T:&%TSV]V97)A
M;&PL@'!E;W!L98!W97)E@&UO<F6';&EK96QY@'!O@'9!97>'=&AE:7*';6%N
M86=E9(!C87)E@'!L86Z'87.'<&]O<H!T:&%N@&-O;7!A<F%B;&6'9F5ESV9O
M<H!S97)V:6-E@'!A=&EE;G!S+H'"5&AE@'-A;66'<W!U9'F'86QS;X!F;W5N
M9(!T:&%T@&QO=X!I;F-O;66':&]U<V5H;VQD<X'H/'"0Q-2PP,###/86YN=6%L
M;'DI@'=E<F6'86QM;W-T@'!W:6-E@&%S@&QI:V5L>8!T;X!R87!E@'!H96ER
M@&UA;F%G962'8V%R98!P;&%N<X!A<X!P;V]R@&-O;7!A<F5D@'=I=&C/;&]W
M@&EN8V]M98!F966\$9F]RA'-E<G9!8V6'<&%T:65N=',N@\$5V96Z'88!T:&]R
M;W5G:(!L:7!E<F%T=7)E@')E=FEE=X!O9H!M86YA9V5D@&-A<F6'\@CR=G,N
M@?,(V9E9='!%0''P')`\$A*G\$E-@'!(!4'T&9O<H!S97)V:6-E@'!L86YS
M@&]F=&5N@&-I=&5D@&)Y@&EN9'5S=')Y@')E<')E<V5N=&%T:79E<X!A<X!F
M:6YD:6YG@&QI='!L98!D:69F97)E;F-E@&)E='E96Z'=&AESW!W;X!F;W)M
M<X!O9H!H96%L=&B'8V%R98!D96QI=F5R>8!W87)N<RR'\''\$%L=&AO=6=H
M@\$A-3X!A;F2':6YD96UN:7!Y@'!L86Z'96YR;VQL965ST',5''+'D''><L
M-R@Z''\$@%0#09V5N97)A;&QY@&AA9(!R;W5G:&QY@&-O;7!A<F%B;&6':&5A
M;'!H@&]U=&-O;65S+(!A@&9E=X!R96-E;G2'<F5S=6QT<X!R96EN9F]R8V6'
M=&AE@&%R9W5M96YTSW!H872';6]N:7!O<FEN9X!H96%L=&B';W5T8V]M97.'
M<&5R9F]R;6%N8V6';75S=(!B98!A@&-R=6-!86R'96QE;65N=(!O9H!A;H!H
M96%L=&B'<WES=&5MSW)E9F]R;8!P;&%N+O'?!/'"*\$!34\$L@\$UA>8'Q."R'
M,3DY-"F'5&AI<X!I<X!N;W2'=&^'<W5G9V5S=(!T:&%T@&&'9F5W@&UA;F%G
M962'8V%R98!H96%L=&B'<&QA;G//9&^';F]T@'!R;W9!9&6'<75A;&ET>8!C
M87)E+(!T:&5Y@&!O+H'"!F]R@&5X86UP;&4L@&&',3DY-8!S='5D>8!B>8!T
M:&6';F%T:6]N86QL>8!R96-O9VYI>F5DST)L=66'0W)O<W.'86YD@\$)L=66'
M4VA!96QD@&9O=6YD@&QI='!L98"<9&EF9F5R96YC99N':6Z';W5T8V]M97.'
M86YD@'-A=&ES9F%C=&EO;H!A;6]N9X!-96!18V%R9<]F966'9F]R@'-E<G9!
M8V6'86YD@\$UE9&EC87)E@\$A-3X!E;G)O;&QE<RZ'@\$AO=V5V97(L@&]V97)A
M;&R'=&AE@)QM86YA9V5D@&-A<F6';65T:&]DFX!O9L]H96%L=&B'8V%R98!F
M:6YA;F-I;F>'86YD@&!E;&EV97)Y@&!O97.';F]T@)QR97-U;2;@&EN@&&'
M<VEM:6QA<H!Q=6%L:7!Y@&]F@&-A<F4L@&5S<&5C:6%L;'F'9F]RSW!O;W)E
M<H!A;F2'<VEC:V5R@'!O<5L87!I;VYS+H#,S%!H98!M;W9E;65N=(!T;X!A
M9&1R97-S@'%U86QI='F':6Z';6%N86=E9(!C87)E@&AA<X!P<F]G<F5S<V5D
M@')A<&ED;'F';W9E<H!T:&6';&%S=(!Y96%R+H'"26[/,3DY-2R'S.'<W!A

M=&5S@'!A<W-E9(!L96=I<VQA=&EO;H!R96=U;&%T:6YG@&UA;F%G962`8V%R
M98!;H!S;VUE@&UA;FYE<BZ`@\$YE=X!9;W)K@%-T871ESW-P96-19FEC86QL
M>8!B<F]K97)E9(!T:&6`6]S=(!C;VUP<F5H96YS:79E@&QE9VES;&%T:6]N
M+(!E<W-E;G!I86QL>8!A@&-O;G-U;65R!P\$V`.8FEL;(!O9H!R:6=H=L
M@,]W:71H@&EN9`5S=)Y+(!P<F]V:61E<G,L@&%N9(!P871196YT@&%D=F]C
M871E<RZ`@\$UA;GF`V:='&AE<V6`<)O=FES:6]N<X!R97%U:7)E@&5V97)Y
M=&AI;F?/9G)O;8!A@'11;65L>8!;G1E<FYA;(!G<FEE=F%N8V6`<)O8V5S
M<X!T;X!C;W9E<F5D@&5M97)G96YC>8!C87)E@&EF@&&`"\$`\$')E87-O;F%B
M;&6`<&5R<V]N\!\$[,]W;W5L9(!H879E@&IU9&=E9(!T:&6`<VET=6%T:6]N
M@&%N@&5M97)G96YC>2Z`@\$-O;F=R97-S@&%L<V^`<&%S<V5D@&QE9VES;&%T
M:6]N@')E<W1R:6-T:6YG@&]N9<]M86YA9V5D@&-A<F6`<)A8W118V6`+2V`
M<V5T=&EN9X!M:6YI;75M@&AO<W!l=&%L@'-T87ES@&9O<H!C:&EL9&)]<G1H
M@'1O@&5L:6UI;F%T98!S;RUC86QL963/(F1R:79E@&)Y(H!D96QI=F5R:65S
M+H"26Z`861D:711;VXL@'1H98!0<F5S:61E;G2`:&%S@&-R96%T962`86Z`
M061V:7-O<GF`0V]U;F-I;(!O;H!#;VYS=6UE<L]0<F]T96-T:6]N@&%N9(!I
M=6%L:71Y@&EN@\$AE86QT:"R`=&AA=(!W:6QL@'1H;W)O=6=H;F`97AA;6EN
M98!T:&6`7-S=66`V:.`<75A;&ET>8!H96%L=&B`8V%R9<]U;F1E<H!M86YA
M9V5D@&-A<F6`<&QA;G,N@(!4:&6`8G5S:6YE<W.`8V]M;75N:71Y@&%L<V^`
M:&%S@'1A:V5N@'-T97!S@'1O@&%D9')E<W.`=&AE@&ES<W5E@&]FSW%U86QI
M='F`=6YD97\*`;6%N86=E9(!C87)E+H!;87)G98!P=7)C:&%S:6YG@&=R;W5P
M<X!A;F2`<W!O;G-O<G.`:&%V98!B96=U;H!T;X!C;VUP87)ESVAE86QT;(!P
M;&%N<X!O;H!T:&6`8F%S:7.`V:`G%U86QI='F';65A<W5R97,L@')E<75I
M<FEN9X!H96%L=&B`<&QA;G.`=&^`<W5B;6ET@'%U86QI='G/:6YF;W)M871I
M;VZ`:6Z`861D:711;VZ`=&^`8V]S=(!P<F]P;W-A;.`=VAE;H!C;VYS:61E
M<FEN9X!H96%L=&B`<&QA;H!C;VYT<F%C='NFX"<@\$UA;GF;@&QA<F=ESYQE
M;7!L;WEE<G.;@(!-96118V%R98!A;F2`365D:6-A:62`86QS;X!H879E@&)E
M9W5N@'1O@')E<75I<F6`<75A;&ET>8!M96%S=7)E@')E<&]R=&EN9RZ`@,S,
M5&AE@&QO=V5R@'%U86QI='F';V:.`5A;'1H@&-A<F6`<)O=FED962`=6YD
M97*`;6%N86=E9(!C87)E@&ES@&&`<)O8FQE;2Z`@\$ET@&ES@&UO<F6`=&AA
M;L]P97)C97!T:6]N@&)A<V5D@&]N@&%N96-D;W1A;(!E=FED96YC92Z`@)Q4
M:&%T@&&@&YU;6)E<H!O9H!S='5D:65S@'1H872`:&%V98"<9F]U;F2`8F5T
M=&5R@&AE86QT;.]O=71C;VUE<X!A;F2`9W)E871E<H!C;VYS=6UE<H!S871I
M<V9A8W11;VZ`\*!1H98!T=V^`87)E@&YO=(!N96-E<W-A<FEL>8!T:&6`<V%M
M92F`:6[/9F5E+69O<BUS97)V:6-E@'!L86YS@'1H86Z`:6Z`;6%N86=E9(!C
M87)E@'!L86YS@'-U<!O<G2`=&AI<X!C;VYC;'5S:6]N+H"2&]W979E<BR`
M=6YR96=U;&%T963/X@\$*`"H`XG!R;W9I<VEO;H!O9H!Q=6%L:71Y@&-A
M<F6`<G5N<X!U<)N`86=A:6YS=("<8V]S=(!C;VYT86EN;65N="Z;@)Q4;YN`
M<V]M98"<97AT96YT+)N`=&AE<F6`:7.`88"<<75A;&ET>2]C;W-TT`5`"+
M`D`80KU"8X`\$@%0#0=)A9&5O9F8NFX!#;&5A<FQY+(!A;GF`86YA;'ES
M:7.`V:`86QT97)N871I=F5S@)QT:&%TFX!E;G-U<F6`G&&`;6EN:6UU;8!L
M979E;(!O9H!Q=6%L:71YFX!C87)E@&UU<W3/8F6`<&%R=&EC=6QA<FQY@&-O
M9VYI>F%N=(!O9H!T:&6`9FEN86YC:6%L@&EM<&QI8V%T:6]N<X!T;X!T:&6`
M<'5B;&EC@&%N9(!P<FEV871E@'-E8W1O<G,N@,SB`@H`"@"#BS%1H98!A
M;'1E<FYA=&EV97.`8V]N<VED97)E9(!I;H!T:&ES@&%N86QY<VES@&%C8V5P
M=(!T:&6`<)E<V5N8V6`;V:.`6%N86=E9(!C87)E@&%S@'1H98!P<F5F97)R
M963/;65T:&]D@&]F@&AE86QT;(!C87)E@&1E;&EV97)Y@&EN@'1H98`Q.3DP
M)W,L@&%N9(!T<GF`=&^`<)O=FED98!A;'1E<FYA=&EV97.`=&AA=(!E;G-U
M<F6`8<]M:6YI;75M@%U86QI='F';V:.`5A;'1H@&-A<F6`=VET:&EN@'1H
M98!M86YA9V5D@&-A<F6`<V5T=&EN9RZ`G\$5S<V5N=&EA;&QY+(!E=F5N@&EF
M@'1H9<]D:7-P87)I='F`8F5T=V5E;H!M86YA9V5D@&-A<F6`86YD@&9E981F
M;W*\$<V5R=FEC98!I<X!A@'-Y<W1E;6EC@'!R;V)L96TL@'=E@&)E;&EE=F6`
M=&AA=,]S>6UP=&]M@')E;&EE9H!W:6QL@&%L;&5V:6%T98!T:&6`=V]R<W2`
M<VED98!E9F9E8W1S+H"1F]RFX!T:&ES@')E87-O;BR`86QT97)N871I=F5S
M@'1H872`9W)E871L><]A;'1E<H!T:&6`<W1R=6-T=7)E@&]F@'1H98!H96%L

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M@'-H;W5L9(!S=')I=F6'=&^'96YS=7)E@&&'6EN:6UU;8!A8V-E<'!A8FQE
M@&QE=F5L@&]F@&AE86QT:(!O=7!C;VUE<X!T:&%TSVUE972'<&%T:65N=(!E
M>'!E8W1A=&EO;G.'6Z'=&AE@&UA;F%G962'8V%R98!S971T:6YG@&9O<H!A
M;&R'<&QA;H!M96UB97)S+H''@,S,S,SQ'J<+!=')%0''P')''\$)UD:.)@'!
M(!4'T/\$#IPOQ24DN@\$-R:7!E<FEAS,Q!+H!);G!R;V!U8W1I;V[,S\$-R:7!E
M<FEA@'-H;W5L9(!R969L96-T@'!H98!P;VQ!8WF';V)J96-T:79E@&%N9(!H
M:6=H;&EG:'2'=&AE@&UO<W2':6UP;W)T86YT@&%S<&5C='';V:'96%C:.,]P
M<FJP;W-E9(!P;VQ!8WF'86QT97)N871I=F6'=&^'86QL;W>'9FJR@&-A<F5F
M=6R'8V]M<&%R:7-O;H!A;F2'8V]N<VED97)A=&EO;BZ'@%1H98!C<FET97)I
M88!O9L]C;W-T+(!A9&%P=&%B:6QI=DL@&5F9F5C=&EV96YE<W.'*&%D97%U
M86-Y*2R'97%U:71Y+(!A;F2'<&]L:7!I8V%L@&9E87-I8FEL:71Y@'AA8V-E
M<'!A8FEL:71Y*<]I9&5N=&EF>8!I;7!O<G!A;G2'87-P96-T<X!O9H!T:&6'
M<&]L:6-Y@&]B:F5C=&EV97,N@(!':79E;H!M86YA9V5D@&-A<F7P"3P<X!C
M;W-T@&-O;G!A:6YM96YTSV9O8W5S+(!C;W-T@&ES@&%N@&EM<&]R=&%N=(!C
M;VYS:6!E<F%T:6]N+H''5&AE@&-H86YG:6YG@&9I96QD@&]F@&AE86QT:(!C
M87)E@&1E;&EV97)Y@&%N9(!T:&7/8V]N<W!A;G2'979O;'5T:6]N@&%M;VYG
M@&9O<FUS@&]F@&UA;F%G962'8V%R98!M96%N@'-U9V=E<W2'=&AA=(!W98!S
M:&]U;&2'8V]N<VED97*'86Z'SV%L=&5R;F%T:79E!P\$'.'861A<'!A8FEL
M:71Y+H''0F5C875S98!M86YA9V5D@&-A<F6':&%S@&9A:6QE9(!T;X!T<F5A
M=(!P;V]R97*'86YD@'-I8VME<L]P;W!U;&%T:6]N<RR'=V6';75S=(!E>&%M
M:6YE@&%N@&%L=&5R;F%T:79E!P\$'.'6UP86-T@&]N@'!H97-E@'!O<'5L
M871I;VYS+H''3V:'8V]U<G-E+(!A;L]A;'!E<FYA=&EV9?'<!/]S@&%B:6QI
M='F'=&^'969F96-T:79E;F':6UP;&5M96YT@&&'6EN:6UU;8!Q=6%L:71Y
M@&]F@&-A<F6';75S=(!B98!E>&%M:6YE9"Z'ST9I;F%L;DL@'=E@&AA=F6'
M=&^'8V]N<VED97*':&]W@&%C8V5P=&%B;&6'86Z'86QT97)N871I=F6':7.'
M=&^'=&AE@&EM<&]R=&%N=(!P;&%Y97)S.H!P;&%N<RS/<&%T:65N=';L@&%N
M9(!P<F]V:6!E<G,N@,S,07.';F]T962'86)O=F4L@&-O;G-I9&5R962'86QT
M97)N871I=F5S@&AA=F6'=&^'=V]R:X!W:71H:6Z'=&AE@&-U<G)E;G2';6%N
M86=E9(!C87)E@'-T<G5C='5R92Z'ST%L=&5R;F%T:79E<X#Q'J,+!6%D9'E
M<W-I;F>'=&AE@/\$#HPOQ\0"D"_'Q'J,+!7-Y<_#HPOQ\0&D"_'Q'J4+!6UA
M;F%G962'8V%R98#P('3P<WES=&5M!\\$(!B>8#Q'Z4+!6%L=&5R:6YG@&9U
M;F!A;65N=&%L@&5L96UE;G!S@&]F@'!H:7//<W!R=6-T=7)E@&AA=F6';F]T
M@&)E96Z':6YC;'5D962':6Z'=&AI<X!A;F%L>7-I<RZ'S,Q"+H!#<FET97)I
M8<S,17%U:71Y.LS,061A<'!A8FEL:71Y.H!4:&6'86)I;&ET>8!T;X!M86EN
M=&%!;H!Q=6%L:71Y@&5F9F5C=&EV96YE<W.'6Z'88!M86YA9V5D@&-A<F6'
M<V5T=&EN9X!A<X!H96%L=&C/8V%R98!D96QI=F5R>8!A;F2'9FEN86YC:6YG
M@&-O;G!I;G5E<X!T;X!E=F]L=F4N@(!4:&ES@&1O97.';F]T@&YE8V5S<V%R
M:6QY@&9A=F]R@&&'6%R:V5T@&)A<V5DSV%L=&5R;F%T:79E+(!B=72':&EG
M:&QI9VAT<X!A;'!E<FYA=&EV97.'=&AA=(!A<F6'9FQE>&EB;&6'96YO=6=H
M@'!O@&%D:G5S=(!F86ER;'F'<7518VML>2[,S\$-O<W0Z@%1H98!D;VQL87*''
M8V]S=(!O9H!;7!L96UE;G!A=&EO;H!O;H!I;F!I=FED=6%L@&AE86QT:(!P
M;&%N<RR';VZ'=&AE@&9E9&5R86R'9V]V97)N;65N=';LSV%N9(!O;H!S=&%T
M98!G;W9E<FYM96YT<RZ'@S-O<W!S@&EM<&QY@'-T<FEC=(!D;VQL87*'8V]S
M='.'=&^'8F6'97AP97)I96YC98!B>8!E86-H@&5N=&ET>2Z'@\$ETT',5''+
M''D''><L-R@Z''\$@%0#0<VAO=6QD@&)E@&YO=&5D@'!H872'8V]S='.'97AP
M97)I96YC962'8GF':&5A;'!H@'!L86YS@'=I;&R':6Z'<&%R=(!O<H!W:&]L
M98!B98!P87-S962';VZ':6Z'=&AESV9O<FV';V':&EG:&5R@'!R96UI=6US
M+H''1G5R=&AE<BR'8V]S='.'=&AA=(!R86ES98!P<F5M:75M<X!W:6QL@&QO
M=V5R@'=A9V5S@&%N9(!C;W)P;W)A=&7/<')O9FET<RR'<F5D=6-I;F>'9F5D

M97)A;(!T87B`<F5V96YU97,N@,S,X#',''''-@)#`#@4&QA;CJ'4&5R@'!A
M=&EE;G2`:6YC<F5A<V6`:6Z`=&AE@&-O<W2`;V:`8V%R98"\$@%IH:7`:7.`
M=&AE@&UA<F=I;F%L@&5C;VYO;6ECSV-O<W2`;V:`<F5G=6QA=&EO;B[0!!<
M`T`"P`"V`DH([@)*",(!<T`P#`''''#8"0P`X\$9E9&5R86PZ@%IO=&%L
M@&9E9&5R86R`9&JL;&%R<J`\$%P`#0`+'`+8"2@CV`DH(P(@%P#0X#',''''
M`-@)#`#@4W1A=&4Z@%IO=&%L@`-T87IE@&IO;&QA<G/0!!<`T`"P`"V`DH
M([@)*",(!<T,Q%9F9E8W1I=F5N97-S.H`H86IE<75A8WDI@&AO=X!F87\*`
M=&JW87)D@&&<VJL=71I;VZ`=V6`8V%N@'!R;V-E962`=VET:(!A=F%I;&%B
M;&6`<F5S;W5R8V5S+LS,4&JL:71I8V%L@\$9E87-I8FEL:71Y.H`"*&%C8V5P
M=&%B:6QI='DI@&IE=&5R;6EN871I;VZ`;V`=VAE=&AE<H!A@'!O;&EC>8!I
M<X!A8V-E<I!A8FQE@'IO@&%C=&J]R<X!I;L]T:&6`<&JL:71I8V%L@'!R;V-E
M<W.`86YD@'IO@&-L:65N='N@,S,S/\$`"J'OQT'D5`'+`D`7T9S10>`\$@
M%0#00.H`\_%)24DN@\$%L=&5R;F%T:79E<S,02Z`3&5G:7-L87IE@\$UE9&EC
M86R`4W1A;F1A<F1SS,Q`+H#R#O)I=6%L:71Y@\$EN9FJR;6%T:6JN.H!R97%U
M:7)E@'!L86YS@'IO@&)E@&%C8W)E9&ET962`86YD@'IO@)E<&]R=(!O9H!A
M=61I=&5D@`-T86YD87)D:7IE9-!%0`"P)``\$`"HP%`"!(!4`T%U86QI
M='F`9&%T82R`86YD@)E<75I<F6`=&AE@`-T87IE@'IO@&ES<W5E@)E<&]R
M=(!C87)D<X!R86YK:6YG@'!L86YS+H#S#O.`@-`\$%0`"P)``&?`^&"@`!
M(!4`T%IH:7.`86QT97)N871I=F6`;&5G:7-L87IE<X!A@'IW;X1P<FJN9V5D
M@&%P<')O86-H.H!R97%U:7)E9(!A8V-R961I=&%T:6JN@&9O<H!A;&R`:&5A
M;'1H@'!L86YSSV%N9(!T:&6`8VJL;&5C=&EO;G.`86YD@)E<&]R=&EN9X!O
M9H!Q=6%L:71Y@&1A=&\$N@(!297%U:7)E9(!A8V-R961I=&%T:6JN@`=O=6QD
M@&5N<W5R98!ASVUI;FEM=6V`<W1R=6-T=7)E@'IO@`-U<!O<G2`<75A;&ET
M>8!C87)E+(!A;F2`=&AE@&-O;&QE8W1I;VZ`86YD@)E<&]R=&EN9X!O9H!Q
M=6%L:71Y@&1A=&`/=VJU;&2`8FJT:(!M;VYI=&]R@&%N9(!P=6)L:6-I>F6`
M=&AE@`%U86QI='F`;V:`8V%R98!D96QI=F5R962`:6Z`=&AA=(!S=)U8W1U
M<F4N@,S,\@]R,2Z`06-C<F5D:71A=&EO;O,\SJ`36%N>8!S=&%T97.`:&%V
M98!B96=U;H!T;X!R97%U:7)E@\$Y#44\$O55)!0X!A8V-R961I=&%T:6JN@&9O
M<H!L:6-E;G-U<F6`;W+0`14`"L`"0`!I-!#Q8`2`5`-!T:&5Y@&AA=F6`
M86QL;W=E9(!.0U%!+U5204.`<F5V:65W@'IO@`-U8G-T:71U=&6`9FJR@'IH
M98!E>'IE<FYA;(!R979I97>`<F5Q=6ER962`9FJR\0*B"_&`<W1A=&7Q`Z(+
M<JL:6-E;G-U<F4N@("S,Q`96YE9FET<SJ`06-C<F5D:71A=&EO;H!B>8!T
M:&6`3F%T:6JN86R`0VJM;6ET=&5E@&]N@%U86QI='F`07-S=7)A;F-E@`A.
M0U%!*8!O<H!5=&EL:7IA=&EO;LJ2979I97>`06-C<F5D:71A=&EO;H!#;VUM
M:7-S:6JN@`A54D%#\*8!G=6%R86YT965S@&&`;6EN:6UU:8!H96%L=&B`9&5L
M:79E<GF`<W1R=6-T=7)E@'IH873/:6YC;5D97.`<75A;&ET>8!I;7!R;W9E
M:65N=(!P<FJ]C97-S97,L@'!H>7-I8VEA;H!C<F5D96YT:6%L<RR`;65M8F5R
M!P\$V.`<FEG:'IS@&%N9,JR97-P;VYS:6)I;&ET:65S+(!P<F5V96YT871I
M=F6`:&5A;'1H@`-E<G9I8V5S+(!U=&EL:7IA=&EO;H!M86YA9V5M96YT+(!A
M;F2`;65D:6-A;(!R96-O<FIS+H`"S,Q\$<F%W8F%C:W,Z@\$%L=&AO=6=H@&%C
M8W)E9&ET871I;VZ`9&J]E<X!P<FJ]V:61E@`-O:66`=6YI9FJR;8!S=)U8W1U
M<F%L@&)A<V4L@'IH:7.`9FJU;F1A=&EO;LJ]I<X!A@&UI;FEM=6TN@(!4:&6`
M8W5R<F5N=(!A8V-R961I=&EN9X!O<F=A;FEZ871I;VYS+(!.0U%!@&%N9(!5
M4D%#@&%R98!;F1U<W1R>8!B87-E9`R`86YDSVQI:V6`=&AE@\$I#04A/(@&)E
M9FJR98!T:&5M+(!T:&5Y@&%R98!S=6)J96-T@'IO@&EN9'5S=)Y@&EN9FQU
M96YC92Z`@\$Y#44&`8W5R<F5N=&QY@&1E;FEE<]A8V-R961I=&%T:6JN@'IO
M@&%B;W5T@#\$Q)8!O9H!A<L>6EN9X!H96%L=&B`<&QA;G,N@(!.;VYE=&AE
M;&5S<RR`=&AE@'!R;V-E<W.`;V:`<F5V:65W@&9O<LJA8V-R961I=&%T:6JN
M@&ES@&&`=7-E9G5L@&5X97)C:7-E@'IH872`<)O;6JT97.`8V%R969U;(!E
M>&%M:6YA=&EO;H!O9H!C=7)R96YT@'!R86-T:6-E<R[,S/(!C(N@\$-O;&QE
M8W1I;VZ`86YD@)E<&]R=&EN9X!O9H!3=&%N9&%R9&EZ962`475A;&ET>8!\$
M871A.O,\X`"@S-O;&QE8W1I;F>`86YD@)E<&]R=&EN9X!Q=6%L:71YT`\$5
M`'+`D`";XH#B0T`\$@%0#0;65A<W5R97.`:&%S@&)E8VJM98!A@'!O<5L
M87*`;65T:&J]D@&JF@&5N<W5R:6YG@`%U86QI=DN@("475A;&ET>8!H96%L

M=&B'8V%R98!M96%N<\JT<F5A=&UE;G2'86YD@&1I86=N;W-T:6.'=&5S='.
M=&AA=(!L96%D@!O@&=O;V2':&5A;'IH@&]U=&-O;65S@&%N9(!T:&%T@&UE
M972'<&%T:65N=,]E>!E8W1A=&EO;G,N@(!";WIH@\$Y#44&'86YD@!IH98!&
M;W5N9&%T:6]N@&9O<H!!8V-O=6YT86)I;&ET>8'H1D%#0U0I@&AA=F6'<F5L
M96%S9630'Q4''L''0!'YRPW*#H''2'5'-!N871I;VYA;(!R96-O9VYI>F5D
M@&EN9&EC871O<G.';V:'<75A;&ET>2Z'@%IH97-E@&UE87-U<F5S@&=A=&AE
M<H!I;F9O<FUA=&EO;H!O;H!B;WIH@&AE86QT.;]O=71C;VUE<X!F;W*'8V]M
M;6]N@!A=&AO;&]G:65S@&%N9(!P871I96YT@'-A=&ES9F%C=&EO;H!S=7)V
M97ES+H'''3D-10?'<!/[S@'-E=(!O9H!Q=6%L:71YSVUE87-U<F5S+(!96%L
M=&B'4&QA;H!%;7!L;WEE<H!A;F2'1&%T88!);F9O<FUA=&EO;H!3972'*\$A%
M1\$E3*2R':6YC;'5D97.'<W5C:(!M96%S=7)E<X!A<X#/= &AE@'!E<F-E;G2'
M;V:'<&%T:65N='.'<F5C96EV:6YG@&9O;&QO=X1U<'869T97*'86Z'86)N
M;W)M86R'<&%P<VUE87(L@!IH98!P97)C96YT@&]F@!A=&EE;G1SSW)E8V5I
M=FEN9X!A<W!!<FEN@&%F=&5R@&AE87)T871T86-K<RR'86YD@!IH98!A;FYU
M86R'9&ES96YR;VQL;65N=(!R871E+H!#;VYS=6UE<H!A9'9O8V%C><]G<F]U
M<'.'&%V98!S=6=G97-T962':6YC;'5D:6YG@!IH98!M96%S=7)E<X!O9H!G
M<FEE=F%N8V6'86YD@&%P<&5A;.'<')O8V5S<V5S@&%N9(!A8V-E<W.'\0*?
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M;6EN:6UU;8!O=71C;VUE<]I;H!T:&6'<W5B<V-R:6)E9(!A<F5A<RZ'1G5R
M=&AE<H!M;W)E+(!T:&5S98!M96%S=7)E<X!A;&QO=X!E;7!L;WEE<G.'86YD
M@!A=&EE;G1S@!1O@&-O;7!A<F7;W5T8V]M97.'86-C<F]S<X!P;&%N<RZ'
M1FEN86QL>2R':G5S=(!B>8!R97%U:7)I;F>'<&QA;G.'=&^'8V]L;&5C=(!I
M;F9O<FUA=&EO;H!G:79E<X!T:&5M@&EN<VEG:'3/:6YT;X!A<F5A<X!N965D
M:6YG@&EM<')O=F5M96YT+H!0;W=E<F9U;(!B=7-I;F5S<V5S@&%N9(!P=7)C
M:&%S:6YG@&%G96YT<X!H879E@&)E9W5N@!IOSW)E<75E<W2'2\$5\$25.'6YF
M;W)M871I;VZ':6Z'861D:71I;VZ'=&^'8V]S=(!P<F]P;W-A;.'=VAE;H!C
M;VYS:61E<FEN9X!I;G-U<F%N8V6'8V]N=')A8W1S+H#/4VEM:6QA<FQY+(!-
M961I8V%I9(!A;F2'365D:6-A<F6';F]W@)E<75I<F6'<&QA;G.'=&^'<F5P
M;W)T@\$A%1\$E3@&UE87-U<F5S+H''@\$AO=V5V97(L@&YO=,]A;&R':&5A;'IH
M@!L86YS@&-O;&QE8W2'86YD@)E<&]R=(!Q=6%L:71Y@&EN9F]R;6%T:6]N
M+H'''S,Q\$<F%W8F%C:W,Z@\$%L=&AO=6=H@'%U86QI='F';65A<W5R97.'87)E
M@!O<5L87(L@!IH97F':&%V98!S979E<F%L@&1R87=B86-K<RZ'1FER<W3/
M;6]N:71O<FEN9X!S;VUE@&AE86QT:(!O=71C;VUE<RR';&5A=F5S@&]T:&5R
M<X!U;F%T=&5N9&5D+(!A;F2'<VEC:V5R@!A=&EE;G1S@=I;&R';F]T@&AA
M=F7/86YY@'%U86QI='F':6YF;W)M871I;VZ'=&^'<F5V:65W+H'''06QT:&]U
M9VB'86YY@'-E=(!O9H!Q=6%L:71Y@&UE87-U<F5S@!1R:65S@!1O@&%C8V]U
M;G2'9F]R@!L86[/8V]L;&5C=&EO;H!D:69F97)E;F-E<RR';65T:&]D<X!D
M;X!V87)Y@&)Y@!L86XL@-U;&QY:6YG@&1A=&&'<F5L:6%B:6QI='F'86YD
M@'9A;&ED:71Y+H'''@(!&=7)T:&5R+;]P871I96YT@'-A=&ES9F%C=&EO;H!S
M=7)V97ES@!1E;F2'=&^':&ED98!Q=6%L:71Y@&-A<F6':7-S=65S@&%S@&UA
M;GF'<&QA;H!M96UB97)S@&1O@&YO=(!U<V7/<&QA;H!S97)V:6-E<RZ'S,SR
M#O)3=&%T98!297!O<G2'0V%R9'/S#O,Z@%-E=F5R86R'<W1A=&5S@!A002Q&
M3"Q55"Q-3BQ.62F':&%V98!B96=U;H!T;X!P=6)L:7-H@/'@!//R97!O<G2'
M8V%R9'/P'P3P@&]NT'\$5''+'D''?@E2"\$P'\$@%0#0:&5A;'IH@!L86YS
M@&]P97)A=&EN9X!I;H!T:&5I<H!S=&%T92Z'@\$5S<V5N=&EA;&QY+(!T:&6'
M<W1A=&6'<F%N:W.'96%C:(!P;&%N@&%C8V]R9&EN9X!T;X!T:&7/<75A;&ET
M>8!M96%S=7)E<X!I=(!H87.'8V]L;&5C=&5D@&%N9(!P;&%C97.'=&AA=(!I
M;F9O<FUA=&EO;H!I;G1O@!IH98!P=6)L:6/P'3P<X!H86YD<RZ'@%-E=F5R
M86S/<W1A=&5S+(!S=6-H@&%S@\$YE=X!9;W)K+(!H879E@&)E96Z'<')O9'5C
M:6YG@)E<&]R=(!C87)D<X!O;H!H;W-P:71A;.'9F]R@'EE87)S+H'''5&AE

M<F6`:/7/979I9&5N8V6`=&AA=(!.97>`66]R:X!3=&%T98!P=6)L:7-H962`
M<F5P;W)T<X!O;H!C;W)O;F%R>8!B>7!A<W.`<W5R9V5R>8!P<F]G<F%M<X!A
M=(!V87)I;W5SSVAO<W!l=&%L<X!D:62`F]T@&=R96%T;F`:6YF;5E;F-E
M@&-O;G-U;65R@&-H;VEC92R`8G5T@)E<W5L=&5D@&EN@&EN=&5R;F%L@&-O
M;7!E=&ET:6]N@&%M;VYGT`,5`+`D`><L-R@Z`\$@%0#0<`)O=FED97)S
M@`!O@&EM<`)O=F6`&5A;`!H@&]U=&-O;65S+H`3EF`&%S@`-E96Z`88!D
M96-L:6YE@&EN@&-O<F]N87)Y@&UO<G!A;&ET>8!B>7!A<W.`<F%T97,NS,S,
M0F5N969I=,Z@%-T87!E@)E<&]R=(!C87)D<X!F;W)C98!P;&%N<X!T;X!C
M;VUP97!E@&]N@%U86QI='F`9&%T88!F;W\*`96UP;&]Y97)S@&%N9(!F;W+/
M<&%T:65N=,N@(!;W)E@&EM<&]R=&%N=&QY@`!H97F`<VAO=X!P;&%N<X!H
M;W>`=&AE>8!R87!E@&%G86EN<W2`=&AE@`-T87!E@&%V97)A9V6`86YD@`!O
M:6YT@&]U=,JA<F5A<X!T;X!l;7!R;W9E@`-E<G9!8V4N@(!0=6)L:6-l='F`
M<W5R<F]U;F!l;F>`<W!A=&6`<F5P;W)T@&-A<F!S@`!R;V)A8FQY@`!U<VAE
M<X!H96%L=&B`<&QA;G!/=&]W87)D@%U86QI='F`;6]R98!T:&%N@&-O;G-U
M;65R@`5S92Z`@,S,l)A=V)A8VMS.H!-86YY@&-O;G-U;65R<X!l9VYO<F4L
M@&-A;FYO=(!R96%D+(!O<H!F86EL@`!O@`5S98!G96YE<F%L@&-O;G-U;65R
M@&EN9F]R;6%T:6]NSV%N9(!H96%L=&B`<&QA;H!C:&]l8V6`7`F^`9&EF
M9F5R96YT+H#,S%-T<G5C='5R93J`26Z`9V5N97)A;"R`=&AE@&EM<&%C=(!O
M9H!l;F9O<FUA=&EO;H!O;H!A@`!R;V-E<W.`=V]R:W.`8F5S=(!W:&5R98!l
M=(!C86Z`8F5S=(!B9<]U<V5D+(!l;H!T:&ES@&-A<V4L@&%T@`!H98!L;V-A
M;(!L979E;"Z`@(!&W\*`=&A!<X!R96%S;VZ`<W!A=&5S@`-H;W5L9(!A9&UI
M;FES=&5R@&%C8W)E9&ET87!l;VXLSV-O;&QE8W2`<75A;&ET>8!l;F9O<FUA
M=&EO;BR`86YD@`!R;V!U8V6`<W!A=&6`<F5P;W)T@&-A<F!S+H`@\$AO=V5V
M97*`88!N87!l;VYA;(!C;V]R9&EN87!l;F?/8V]M;6ET=&5E@&]F@`-T87!E
M@&EN<W5R86YC98!C;VUM:7-S:6]N97)S@&%N9(!H96%L=&B`<`)O9F5S<VEO
M;F%L<X!S:&]U;&2`8F6`8V]N=F5N962`=&^`<V5TSVUI;FEM=6V`<75A;&ET
M>8!S=&%N9&%R9/Q`)H+2R`=VA!8VCQ`9H+2\$"FPOQ@`!H873Q`YL+8!S
M=&%T97.`75S=(!U<V4L@&)U=(!W:&EC:(!C86Z`8F6`97AC965D962`8GF`
M<W!A=&6`<W!A;F!A<F!S+H#,S,S,\@CR!7%U:7!Y\PCS.H!&W\*`=&AE@&UO
M<W2`<&%R="R`=&A!<X!A;`!E<FYA=&EV98!E;G-U<F5S@&&`6EN:6UU;8!O
M9H!Q=6%L:7!Y@&]U=&-O;65S@&9O<H!A;&S0`14`"L`"0`!%R5G("2`5
M`-!P;W!U;&%T:6]N<RR`.6Z`=&AO<V6`87)E87.`9F]R@`=H:6-H@%U86QI
M='F`9&%T88!A<F6`8V]L;&5C=&5D@&%N9(!M;VY!=&]R960N@(!!8V-R96!l
M=&%T:6]NSV%S<W5R97.`88!M:6Y!;75M@`-T<G5C='5R98!F;W*`<75A;&ET
M>8!D96QI=F5R>2R`88!N96-E<W-A<GF`8G5T@&YO=(!S=69F:6-l96YT@&-O
M;F!l=&EO;H!F;W+<75A;&ET>8!C87)E+H`36%N>8!O9H!T:&6`&5A;`!H
M@&]U=&-O;66`<75A;&ET>8!l;F!l8V%T;W)S@&!O@&%D9)E<W.`&]W97*`
M:6YC;VUESW!O<5L87!l;VYS+OS`F`OQ!0*7" _&`0.7" \_%-86YY@&]F@`!H
M97-E@%U86QI='F`:7-S=65S@&!O@&%D9)E<W.`&]W97*`:6YC;VUE@`!O
M<5L87!l;VXN!0&8" _&`@\$9O<H!E>&%M<&QE+(!l4l)4X!S<&5C:69!8V%L
M;'F`8V]N=&%l;G.`365D:6-A:62`<W!E8VEF:6.`6YD:6-A=&]R<RR`<W5C
M:(!A<]-96!l8V%l9(!E;G)O;&QM96YT+(!A<X!W96QL@&%S@&AE86QT:(!O
M=7!C;VUE<X!P<F]M:6YE;G2`.6Z`=&AO<V6`<&]P=6QA=&EO;G,L@`-U8VB`
M87//8VA!;&!H;V]D@&EM;75N:7!A=&EO;H!S=&%T=7,L@&]R@&9L=8!S:&]T
M<X!F;W*`;VQD97\*`86YD@&A!9VB\$<FES:X!A9`5L=,N@\$AO=V5V97(L@`!H
M97-ESVUE87-U<F5S@`!R;V)A8FQY@`=!&R`F]T@&EM<`)O=F6`97%U:7!Y
M@&9O<H!S:6-K97*`<&]P=6QA=&EO;G/Q`!D+8!W:7!H@`5N8V]M;6]N@`!A
M=&AO;&]G:65S!0.9" _\$N@,S,\@CR0V]S=,(\SK0!A4`"L`"0`!;"V`*P`
M`2`5`-#@,P`"V`D,`!0;&%N.H!#;VQL96-T:6YG@`!E<F9O<FUA;F-E
M@&EN9F]R;6%T:6]N@&-O<W!S@`!0P+C4P@`!O@`!0Q+C`P@`!E<H!E;G)O;&QE
M98!O<L]A8F]U=(`D-S`L,#`P+H`"06-C<F5D:7!A=&EO;H!C;W-T<S]`86)O
M=72`)#0P+#`P,(!P97*`86-C<F5D:7!A=&EO;H!A;F3/)#(Q+#`P,(!R96%C
M8W)E9&ET87!l;VZ`9F5E+H#0!!<`T`"P`"V`DH(j@)\*",(!<`T.`P#`"
M`#8"0P`X\$9E9&5R86PZ@\$-O<W2`9F]R@\$-O;W)D:6YA=&EN9X!#;VUM:7!T

M966`)#2';6EL;&EO;H'H8F%S962';VZ'4%!20R]04D]004//9&]L;&%R<RG0
M!!<'T'"P'"V'DH(J@)*","(!<T.'P#''''#8"0P'X%-T871E.H!#;W-T
M@&9O<H!P<F]D=6-I;F>'<F5P;W)T@&-A<F1S.H!A8F]U=('D,S'P+#'P,('H
M3EF'97-T:6UA=&4IT'07''-'L'M@)*"/8"2@C'B'7'-#,\@CR169F96-T
M:79E;F5S<_,(S'J'06=A:6XL@&%C8W)E9&ET871I;VZ'9F]R8V5S@!'L86YS
M@'1O@&AA=F6'88!M:6YI;75M@'-T<G5C='5R98!U;F1E<M'!'%0''P')`\$8
M#&@''''!(!4'T&%C8W)E9&ET871I;VXN@(!(:W=E=F5R+(!S=')U8W1U<F6'
M9&]E<X!N;W2';F5C97-S87)I;'F'=)A;G-L871E@&EN=&^<75A;&ET>2Z'
M@\$UI;FEM=6V'<75A;&ET><]M96%S=7)E<X!D;X!F;W)C98!P;&%N<X!T;X!P
M97)F;W)M@&EN@&-E<G1A:6Z'9&5S:6=N871E9(!A<F5A<RR'8G5T@'1H97F'
M9&^';F]T@&=A=7)U;G1E98!Q=6%L:71YSV-A<F6':7.'86QL@&%R96%S+H"
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M:61U86R'8V]N<W5M97)S@')A<F5L>8!U<V6'<5B;&ES:&5D@&1A=&&';V:'
M=&AI<X!K:6YD+H#;S.'P#''''#8"0P'X\$AE86QT:(!/=71C;VUE<S'J'5&AE
M@&AE86QT:(!P;&%N@'=I;&R'<)O=FED98!Q=6%L:71Y@&-A<F6'872';&5A
M<W2':6Z'=&AO<V7/87)E87.'=&AA=(!H879E@&UI;FEM=6V'<W1A;F1A<F1S
M@&%N9(!W;&EC:(!A<F6'8F5I;F>'>65A<W5R960N@(!(:W=E=F5R+;]T:&5S
M98!O=71C;VUE<X!D;X!L:71T;&6'9F]R@&%R96%S@&YO=(!M96%S=7)E9"Z'
MT'07''-'L'M@)*"/8"2@C'B'7'-#;X#',''''-@)#'#@4&%T:65N=(!%
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M''-'L'M@)*"/8"2@C'B'7'-#,\@CR4&]L:7118V%L@\$9E87-18FEL:71Y
M\PCS.H!;&R';V:'=&AE<V6'8V]M<&]N96YT<X!A<F6'86QR96%D>8!O8V-U
M<G)I;F>'>6Z'=&AE@&UO<F6'8V]N8V5R;F5DT'\$5''+'D'<(<\$A@:'\$@
M%0#0<')I=F%T98!M87)K971S+(!M86MI;F>'>75A;&ET>8!D871A@&UO<F6'
M<&]L:7118V%L;'F'9F5A<VEB;&6'=&AA;H!M86YY@&]T:&5R@&9O<FUS@&]F
MSW)E9W5L871I;VXN@(!;'1H;W5G:(!T:&6'04%(4(!O<'!O<V5S@&%L;(!R
M96=U;&%T:6]N@&%S@')A:7-I;F>'>8V]S='.'=VAI8VB'8W5T@&EN=&^<&%T
M:65N=;]C87)E+(!T:&6'04%(4(!A8W1U86QL>8!E;F1O<G-E9(!M:6YI;75M
M@%'U86QI='F'<W1A;F1A<F1S@'=H96Z';F%T:6]N86R':&5A;'1H@&EN<W5R
M86YC9<]W87.'8F5I;F>'>8V]N<VED97)E9"Z'@(!/8G9I;W5S;'DL@'1H98!Q
M=6%L:71Y@')E=FEE=X!I;G1E<F5S=(!G<F]U<'.'*\$Y#44\$55)!0RQ&04-#
M5"G/9F%V;W*'<F5Q=6ER962'<75A;&ET>8!I;F118V%T;W)S+H'"0V]M8FEN
M962'<&%T:65N=(!A;F2'<)O=FED97*'9W)O=7!S+(!S=6-H@&%S@'1H98!#
M;V%L:71I;V[/9F]R@&-O;G-U;65R@%'!R;W1E8W1I;VZ'86YD@%'%U86QI='F'
M:6Z'2&5A;'1H@&-A<F6'<W5P<&]R=(!T:&6'8V]L;&5C=&EO;H!A;F2'=7-E
M@%'U86QI='F'9&%T82S/8G5T@'5L=&EM871E;'F'=V]U;&2'<)E9F5R@&%N
M@&%L=&5R;F%T:79E@'1H872'<F]L;&5D@%'U86QI='F':6YF;W)M871I;VZ'
M:6YT;X!A@&QA<F=E<H!R96=U;&%T:6]NSV]F@'1H98!M86YA9V5D@&-A<F6'
M:6YD=7-T<GDN@;S,\@CR061A<'1A8FEL:71Y\PCS.H!4:&ES@&%P<')O86-H
M@'=O=6QD@'!R;W9E@&9A:7)L>8!A9&%P=&%B;&4N@\$%S@&AE86QT:(!C87)E
M@&5V;VQV97,L@&-O;&QE8W1E9-'!%0''P')`\$\$E0A)'!(!4'T&UE87-U
M<F5S@&%N9(!A8V-R961I=&%T:6]N@&-O;7!O;F5N='.'8V]U;&2'8F6';6]D

M:69I962'86YD@&%D:G5S=&5D+H""1D%#0U2'8VET97.'=&AI<X!A<\]O;F6'
M;V:.'=&AE@&)I9V=E<W2'8F5N969I='.';V:.'<75A;&ET>8!M96%S=7)E<RZ'
M2&]W979E<BR'=&AE<F6'=V]U;&2'8F6'88!T:6UE@&QA9X!B97!W965NSVYE
M=X!T96-H;FEQ=65S@&%N9(!A;GF'='EP98!O9H!M96%S=7)E+LS,S\$,N@\$]M
M8G5D<VUA;B]);F1E<&5N9&5N=(12979I97?,S\$0N@\$-O;G-U;65R@\$)I;&R'
+;V:'4FEG:'!S@)MM
,

end

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE: 1-NOV-1996 08:20:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01IBBPGULEHS00CIEQ@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 01 Nov 1996 08:20:06 -0400 (EDT)

Received: from hcfa.gov (158.73.85.22) by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01IBBPFBN3CW000082@STORM.EOP.GOV> for levi_j@a1.eop.gov; Fri,
01 Nov 1996 08:18:53 -0700 (MST)

Received: from HCFA-Message_Server by hcfa.gov with Novell_GroupWise; Fri,
01 Nov 1996 08:18:23 -0500

X-Mailer: Novell GroupWise 4.1

===== END ATTACHMENT 1 =====